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Abstract 
One of the main focuses in Huntington’s disease (HD) research, as well as in most of 
the neurodegenerative diseases, is the development of new therapeutic strategies, as 
currently there is no treatment to delay or prevent the progression of the disease. 
Neuronal dysfunction and neuronal death in HD are caused by a combination of 
interrelated pathogenic processes that lead to motor, cognitive and psychiatric 
symptoms. Understanding how mutant huntingtin impacts on a plethora of cellular 
functions could help to identify new molecular targets. Although HD has been 
classically classified as a neurodegenerative disease affecting voluntary movement, 
lately cognitive dysfunction is receiving increased attention as it is very invalidating for 
patients. Thus, an ambitious goal in HD research is to find altered molecular 
mechanisms that contribute to cognitive decline. In this review we have focused on 
those findings related to corticostriatal and hippocampal cognitive dysfunction in HD, 
as well as on the underlying molecular mechanisms, which constitute potential 
therapeutic targets. These include alterations in synaptic plasticity, transcriptional 
machinery, and neurotrophic and neurotransmitter signaling.  
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INTRODUCTION 
In Huntington’s disease (HD), the trinucleotide (CAG) repeat expansion in the 
huntingtin gene results in an extended polyglutamine (polyQ) tract in the huntingtin 
protein which induces a cascade of pathological changes leading to neuronal 
dysfunction and neurodegeneration. HD is characterized by degeneration of the 
striatum and cortical atrophy (1,2), but other brain areas such as the hippocampus, 
thalamus, globus pallidus, and substantia nigra are also affected (2-9). Importantly, 
evidence from both patients (10) and mouse models (11,12) indicates that cell death 
does not occur until late stages of the disease, indicating that neuronal dysfunction, 
including abnormal synaptic plasticity, is an early pathogenic event that precedes 
neuronal death and leads to HD symptoms. Having this in mind, research is focused on 
finding common molecular targets to prevent cognitive impairment by 
preserving/restoring neuronal function at early disease stages, which hopefully will 
help to avoid subsequent neuronal death. Thus, the identification of these early 
cellular and molecular pathogenic events in HD represents an important milestone in 
the design of new therapeutic approaches to cure or delay disease progression. To 
achieve this goal it is mandatory to build from data obtained by analyzing HD mouse 
models, as new therapeutic strategies can be developed based on those altered 
molecular mechanisms found to contribute to cognitive impairment in HD. 
 
Cognitive dysfunction in HD patients  
The first paper on cognitive function in HD was published in 1974 (13), and relevant 
publications on this issue have emerged at an accelerating rate since then (reviewed in 
(14)), so that the nature and variety of cognitive decline in HD patients are well 
documented and have been the focus of recent reviews (15-19). 
 
Corticostriatal dysfunction 
Although HD is characterized by a progressive degeneration of medium-sized striatal 
spiny neurons (MSNs) (20,21), functional and morphological changes in the neocortex 
have been proposed as the initial triggers of striatal pathology, and it has been put 
forward that cortical changes are fundamental for the onset and progression of the HD 
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phenotype, in both humans and animal models (reviewed in (22)). In this context, HD 
patients at pre-symptomatic stages exhibit alterations in tasks related to the 
neocortical function, like those that require strategy shift (23,24), and also in executive 
function, in verbal fluency (25,26), in procedural learning, in planning, and in explicit 
motor learning (25,27-29). Moreover, early corticostriatal alterations in HD patients 
have been further attested by neuroimaging studies showing impaired corticostriatal 
functional connectivity in pre-symptomatic HD subjects (30-32). These corticostriatal 
alterations correlate with decreased activity in the frontal cortex and putamen (33). In 
mid-stage clinically symptomatic HD patients, executive function, verbal fluency, 
perceptual speed and reasoning are strongly affected (34,35), while at more advanced 
disease stages, a sub-cortical dementia gradually develops, with alterations in several 
simple and complex cognitive functions involving slow information processing, 
decreased motivation, depression, apathy and personality changes (36,37). 
Marked nuclear and cytoplasmic accumulation of mutant huntingtin has been 
reported in cortical pyramidal neurons, which overlaps with cortical dendritic 
abnormalities in postmortem brain of patients with low-grade striatal pathology 
(38,39). Indeed, abundant mutant huntingtin is evident in numerous cortical 
dystrophic axons that project to the striatum (40). It has also been reported that stage 
I and II HD patients exhibit specific thinning of the neocortex (5,41). Overall, these 
findings indicate that cortical changes are fundamental to the onset and progression of 
the HD phenotype, evidencing a central role of the cortex at early stages of HD.  
 
Hippocampal dysfunction 
The hippocampus, together with the amygdala and the nucleus accumbens, forms the 
central axis of the limbic system that plays a key role in the formation of declarative 
memory, spatial learning and awareness, navigation, object recognition and visual 
memory, as well as in executive functions (42-49). Studies in HD patients have mainly 
focused on the cognitive functions involving the corticostriatal circuitry, whereas those 
related to hippocampal connectivity are still poorly analyzed. Nevertheless, there is 
clear evidence of hippocampal morphological alterations in HD patients such as a 
reduction in hippocampal volume (4,8,9) and the presence of mutant huntingtin 
aggregates (3,6). Moreover, some cognitive tasks analyzed in human studies such as 
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the evaluation of spatial working memory, spatial recognition memory, object 
recognition memory, episodic memories and some forms of associative learning, can 
involve the participation of the hippocampus and temporal lobe structures 
(43,45,48,50-52). Thus, although no severe deficits in spatial working memory have 
been shown in pre-symptomatic HD patients, their latency in performing these tasks is 
higher than in control individuals (24,27), whereas recognition memory has been 
shown to be affected in pre-symptomatic HD-gene carriers (53). A recent study using 
tests analogous to those employed in HD mouse models describes hippocampal-
dependent impairments in patients in early HD stage, ahead of motor symptoms. 
Patients are unable to learn the location of the platform in the virtual Morris water 
maze and performance correlates to the estimated years to disease onset (54). In 
early-mild symptomatic HD patients, alterations in associative learning, spatial short-
term memory, spatial working memory and recognition memory have been described 
(55,56). Importantly, in middle and more advanced disease stages, a global cognitive 
decline is observed in HD patients (34-37). These alterations involve both 
corticostriatal and hippocampal dysfunction. However, it seems that declarative 
memories more related to hippocampal and corticotemporal functions are not as 
altered as procedural learning, more related to corticostriatal integrity. Actually, in HD 
patients, the hippocampus compensates for gradual dysfunction of the caudate 
nucleus, helping to maintain route recognition close to normal performance (57,58).  
 
Impaired synaptic plasticity and cognitive dysfunction in HD mouse models 
The discovery of the gene mutation responsible for HD occurred in 1993 (59), and this 
allowed for the generation of several HD genetic models. Although the disease has 
been reproduced in diverse species, mouse models are the most extensively used. The 
different genetic mouse models differ in their phenotypes as a result of the way 
mutant huntingtin is inserted into the murine genome: 1) exon-1 transgenic mice: R6, 
N171-82Q and the conditional HD94Q-tet off mice, and 2) full-length transgenic mice: 
Yeast artificial chromosome (YAC), bacteria artificial chromosome (BAC)HD and knock-
in mice (Table 1). HD mouse models display alterations in synaptic plasticity (Table 2) 
and replicate the cognitive impairment observed in HD patients (Table 3), thus 
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providing an excellent opportunity to study the underlying molecular mechanisms and 
to test potential treatments for transfer to patients (for review see (60-63)).  
Electrophysiology is one of the best characterized methods to evaluate synaptic 
plasticity. Long-term potentiation (LTP) and long-term depression (LTD) are commonly 
used paradigms to assess synaptic properties (42,64-66). Several studies indicate that 
excitatory synapses exhibit the most important alterations in HD (67-69), and 
numerous reports have concluded that corticostriatal and hippocampal synaptic 
plasticity are impaired (Table 2). These studies suggest that synaptic deficits, including 
alterations in synaptic transmission, plasticity and aberrant spine density/morphology, 
may be the initial triggers of the cognitive deficits observed in HD (70). Interestingly, a 
recent study using a corticostriatal co-culture cell model from wild-type and YAC128 
mice demonstrated impaired development of excitatory synaptic connectivity and 
reduced dendritic complexity in YAC128 MSNs. Moreover, a number of other HD-
associated synaptopathy features previously reported in the striatum of HD mice at 
mid-to-late stages (71) were also observed (72). Remarkably, mutant huntingtin is 
required pre- and post-synaptically to elicit these effects, which is in agreement with 
previous findings showing that its expression selectively in either striatal or cortical 
neurons is insufficient to fully recapitulate HD behavioral and neuropathological 
phenotype (73-75). In the same line, the absence of mutant huntingtin in cortical 
afferents partially improves striatal neuronal activity and behavior in a conditional 
mouse model of HD (76). Altogether, these studies point to the existence of cell-cell 
pathogenic interactions that shape the progression of striatal deficits. 
 
Altered mechanisms underlying synaptic dysfunction and cognitive 
impairment in HD 
Neuronal dysfunction and cognitive impairment precede motor symptoms and 
neuronal death in HD patients, and they occur long before (or in the absence) of cell 
death in HD mouse models, suggesting that the early cognitive deficits may be a 
consequence of synaptic dysfunction rather than of cell loss (126,155-158). In fact, 
huntingtin binds to a wide range of intracellular proteins, many of them responsible 
for synaptic transmission (159), and mutant huntingtin is present in pre-synaptic 
(160,161) and post-synaptic terminals (162), where it interacts with several synapse-
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related proteins impairing synaptic function in HD mice (161,163,164). Moreover, the 
presence of mutant huntingtin alters numerous cellular and molecular mechanisms 
including protein aggregation, protein-protein interaction, calcium signaling, 
mitochondrial function, transcriptional regulation and chromatin remodeling, vesicle 
transport, neurotransmitter release and receptor activity (163-165). Potentially, all 
these alterations can impact on neuronal functioning, synaptic plasticity and, 
ultimately, cognitive function. Nevertheless, in the following sections we will mainly 
focus on those altered mechanisms that have been demonstrated to participate in 
neuronal dysfunction leading to synaptic plasticity deficits and/or cognitive 
impairment. 
 
Spine loss 
Dendritic spines play critical roles in synaptic transmission and plasticity because 
changes in their morphology and density modulate the formation and maintenance of 
the synapses, enabling the dynamics of neural circuitry (166-168). Several studies 
demonstrate synaptic alterations in MSNs neurons (20,169) and in prefrontal cortical 
pyramidal neurons (170) from HD post-mortem brain samples. Furthermore, studies in 
HD mouse models also provide evidence for altered dendritic morphology (Table 2). 
Here, we describe the mechanisms that contribute to these alterations.  
 
RhoGEF/GAP signaling: Kalirin-7  
Kalirin-7, a postsynaptic brain-specific guanine exchange factor protein for Rho-like 
small GTPases (171), has emerged as a key regulator of excitatory synapses. 
Overexpression of Kalirin-7 causes an increase in dendritic spine density, spine size and 
synapse number, while Kalirin-7 knockdown promotes spine shrinkage and loss in 
cultured hippocampal and cortical neurons (172-175). Importantly, and consistent with 
in vitro experiments, these alterations in excitatory synapses correlate with a decline in 
the magnitude of the hippocampal LTP and reduced glutamatergic synaptic 
transmission in the cortex, and impaired cognitive function (173-177), thus supporting 
a role for Kalirin-7 in learning and memory processes through the modulation of 
structural plasticity. Interestingly, Kalirin interacts with huntingtin-associated protein 1 
(178), and alterations in excitatory synapses occur at early disease stages in HD animal 
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models (67,68,134). These synaptic alterations have been suggested as contributing to 
cognitive symptoms in both HD patients and animal models (56,120,147,149). In a 
recent study, and following a broad analysis of synaptic-related proteins such as NMDA 
(GluN1 and GluN2B) and AMPA (GluA1) receptor subunits, presynaptic (VGlut1 and 
synaptophysin) and postsynaptic (Kalirin-7, PSD95, Shank3 and CaMKII) scaffolding and 
signaling proteins, only Kalirin-7 showed an early and specific reduction in the cortex of 
Hdh
Q7/Q111
 and R6/1 mice, which correlates with cortical dendritic spine alteration, 
impaired corticostriatal synaptic plasticity and motor and procedural learning 
behavioral deficits in 2- and 6-month-old Hdh
Q7/Q111
 mice (136). Supporting the 
hypothesis that loss of Kalirin-7 in the cortex of young HD mice could be associated 
with the early loss of excitatory synapses in HD, Kalirin-7 overexpression restores the 
number of cortical glutamatergic synapses in mature cultured HD cortical neurons 
(136).  
 
GluN3A 
NMDARs play crucial roles in remodeling and maintaining excitatory synapses, and 
their activity is altered in MSNs from HD mice (179). NMDAR hyper-function can be 
detected in HD MSNs at early stages (180,181), well before synapse and spine loss, 
behavioral deficits and neuronal death, pointing to signaling through these receptors 
as a key player in the HD pathogenic cascade. 
PACSIN1 controls the endocytic removal of GluN3A-containing NMDARs (182). 
GluN3A is highly expressed in the brain during early postnatal development to prevent 
premature synapse plasticity and stabilization, but its expression declines afterwards 
(130,183-185). Nevertheless, a recent study found that mutant huntingtin binds to and 
sequesters PACSIN1, causing its subcellular redistribution away from the synapse and 
promoting accumulation of GluN3A-containing NMDARs at the surface of striatal 
neurons. In agreement, GluN3A levels are increased in human HD striatum and in 
striatal membrane fractions obtained from distinct HD mouse models including R6/1, 
YAC128 and Hdh
Q111
 knock-in mice (130), suggesting that this redistribution of GluN3A 
has a pathological role. The contribution of GluN3A reactivation in MSNs as an 
important factor in HD pathogenesis receives support from the finding that 
overexpression of GluN3A replicates the reduced synaptic connectivity observed in 
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MSNs from YAC128 mice, whereas lack of GluN3A corrects the early enhancement of 
NMDAR currents and prevents both early and progressive dendritic spine pathology in 
MSNs from YAC128 mice. Importantly, it also ameliorates striatum-dependent motor 
and cognitive decline (130). Thus, these studies reveal a novel early disease 
mechanism that mediates NMDAR dysfunction and synapse loss in HD MSNs. 
 
Store-operated Ca
2+ 
entry 
GluN3A deletion experiments suggest that GluN3A expression is necessary 
to/permissive of HD pathogenesis (130). Nevertheless, other parallel mechanisms 
seem to be set in motion by the presence of mutant huntingtin, leading to spine loss in 
HD MSNs. Dysregulation of intracellular neuronal Ca
2+
 signaling plays a role in HD 
progression (186-188). Mutant huntingtin interacts with type 1 inositol-1,4,5-
trisphosphate receptor (InsP3R1), a neuronal endoplasmic reticulum (ER) Ca
2+
 release 
channel, causing its overactivation and excessive Ca
2+
 release from the ER (189,190). 
Ca
2+
 release from the ER stimulates neuronal store-operated Ca
2+
 entry (nSOC) 
channels in the plasma membrane (191), and this pathway plays an important role in 
the maintenance of postsynaptic mushroom spines in hippocampal neurons (192-194). 
Interestingly, elevated nSOC was reported in cultured MSNs from YAC128 mice (195), 
suggesting that aberrant InsP3R1 function and disrupted ER Ca
2+
 homeostasis could 
contribute to spine loss in MSNs in HD. Interestingly, InsP3R1 knockdown suppresses 
Ca
2+
 leak from the ER, reduces nSOC levels in spines and is sufficient to prevent spine 
loss in YAC128 MSNs (131).  
 
Impaired neurotrophic signaling: TrkB/p75
NTR
 imbalance 
A deficit in neurotrophic support is considered a key player in HD neuropathology. In 
particular, a reduction in BDNF protein levels was reported in several brain regions of 
HD patients and mouse models (165,196-200). However, this general finding has not 
been replicated in a recent study where cortical BDNF mRNA levels were assessed in 
BACHD and heterozygous Q175 knock-in mice using multiple primers and reference 
genes (201), thus challenging the view that this neurotrophic deficit is a major 
pathogenic mechanism in HD. 
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BDNF exerts trophic effects by binding to its receptors TrkB and p75
NTR
. BDNF 
binding to TrkB receptor has been shown to promote neuronal survival (202,203), 
while BDNF binding to p75
NTR 
could either potentiate Trk function (204-207) or activate 
cell death cascades (208-210). Notably, whereas BDNF induces hippocampal LTP 
through TrkB (211), p75
NTR
 has been involved in regulating LTD without affecting LTP 
(212,213) (for review see (214)). These alterations in synaptic transmission are 
associated with structural changes. Thus, a deficiency in BDNF-mediated intracellular 
signaling causes dendritic abnormalities in the striatum and cerebral cortex (215,216), 
while activation of p75
NTR 
blocks axonal and dendritic elongation and arborization by 
activation of RhoA, a Rho GTPase that negatively regulates neurite elongation and 
actin assembly (213,217).  
Importantly, reduced TrkB levels have been reported in HD cellular and mouse 
models, as well as in HD patients (218-220). Moreover, there is increased p75
NTR
 mRNA 
expression in the caudate, but not in the cortex, of HD patients (220). Therefore, there 
is an imbalance between TrkB and p75
NTR
 expression in the caudate nucleus of HD 
patients, and in the striatum and hippocampus, but not in the cortex, of HD mouse 
models at early stages of the disease (135,221), suggesting that this imbalance 
contributes to early and progressive HD pathology. Interestingly, genetic normalization 
of p75
NTR 
in Hdh
Q7/Q111
 mice rescues hippocampal synaptic plasticity and memory 
function, and prevents hippocampal dendritic spine alterations, likely by normalization 
of RhoA GTPase activity (107,135). Reinforcing the role of p75
NTR
 in cognitive deficits in 
HD, overexpression of p75
NTR
 in the hippocampus of wild-type animals reproduces 
those memory deficits observed in HD mice (135,135), while specific hippocampal 
p75
NTR
 knockdown prevents the manifestation of cognitive impairment. Together, 
these findings demonstrate that p75
NTR
 upregulation plays a role in the synaptic and 
learning and memory deficits observed in HD mice. In agreement with these data, 
overexpression of p75
NTR 
in hippocampal neurons decreases spine density (222), while 
null p75
NTR
 mice exhibit increased hippocampal dendritic spine density, improved 
spatial learning and enhanced LTP (223,224). In addition, Plotkin and colleagues have 
shown that although cortical production of BDNF, its delivery to the striatum and 
activation of TrkB are normal in BACHD and heterozygous knock-in zQ175 HD mice, 
BDNF fails to support corticostriatal LTP specifically at corticostriatal synapses of the 
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indirect pathway. Importantly, this kind of plasticity can be rescued by knocking down 
p75
NTR
 or inhibiting its downstream targets RhoA, ROCK and phosphatase and tensin 
homolog deleted on chromosome 10 (PTEN), indicating that enhanced signaling 
through p75
NTR
 and PTEN antagonizes TrkB function and corticostriatal LTP (201). It 
remains to be determined whether this improvement in corticostriatal connectivity 
can be reproduced in other HD models, and whether it translates into an amelioration 
of corticostriatal-dependent learning and/or motor symptoms.  
 
Cognitive impairment  
Adenosine type 2A receptor 
HD mouse models display reduced reversal learning and working memory deficits 
(102,120,147-149,154,225-229) like early HD patients (230,231). This type of cognitive 
impairment, which significantly affects the patient's quality of life, represents a 
primary dysfunction of the corticostriatal pathway (67,232). In a recent study, Chen 
and colleagues (233) evaluated the ability of adenosine type 2A receptor (A2AR) 
inactivation to reverse the deficits in working memory and synaptic plasticity at early 
stages of HD. Their results show that genetic or pharmacological inactivation of A2AR 
prevents working memory deficits in R6/2 mice, without modifying motor dysfunction. 
Moreover, although wild-type and R6/2 mice display similar LTD and LTP at 
corticostriatal synapses, and pharmacological blockade of A2AR inhibits LTP to a similar 
extent in both genotypes, it selectively reduces LTD amplitude in mutant mice (233). 
Thus, striatal A2AR emerges as a novel target to fight against the cognitive inflexibility, 
namely working memory impairment, reported in the prodromal phase of HD (18,231).  
 
PKA overactivation  
Synaptic plasticity and learning and memory processes depend on an appropriate 
balance between kinase and phosphatase activities (234-236). Changes in the 
expression and activity of different phosphatases (237-246) and kinases 
(139,242,243,247-253) (and reviewed in (254)) have been reported in HD models and 
human brain, suggesting that aberrant function of these proteins likely contributes to 
HD pathogenesis. Although alterations in distinct phosphatases can potentially 
contribute, directly or indirectly, to synaptic plasticity deficits and cognitive decline in 
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HD, this issue remains to be directly addressed (230). Conversely, it has been 
demonstrated that adenosine 3’5’ cyclic-monophosphate (cAMP)-dependent protein 
kinase (PKA) overactivation contributes to hippocampal-dependent synaptic and 
cognitive deficits in exon-1 HD mice (110,139). 
The PKA pathway is known to regulate specific types of long-term synaptic 
plasticity (reviewed in (255)), and to play a critical role in hippocampal-dependent 
learning and memory formation (256,257), but persistent and aberrant activation of 
PKA can lead to memory impairment (240,256,258-260). Likewise, increased 
hippocampal PKA activity leads to cognitive dysfunction in R6/2 mice as demonstrated 
by the beneficial effect of intra-hippocampal injection of Rp-cAMPs, a PKA inhibitor, on 
recognition memory (139). Reinforcing these findings, cAMP levels are higher in 
hippocampal nerve terminals from R6/1 mice than in controls, and dopamine type 1 
(D1) and A2A receptors display increased response to their ligands in mutant mice. 
This leads to PKA overactivation in the hippocampus and participates in an occlusion 
mechanism (110). In fact, a combined chronic blockade of D1R and A2AR, but not a 
single acute or a chronic blockade of either receptor alone, normalizes PKA activity in 
the hippocampus and ameliorates cognitive dysfunction in R6/1 mice (110). Moreover, 
and in contrast to vehicle-injected mutant mice, R6/1 animals injected daily with 
SCH23390 (D1R antagonist) plus SCH58261 (A2AR antagonist) display a significant LTP 
induction in vivo. Overall these data show that D1R and A2AR blockade normalizes 
hippocampal PKA activity, enhances synaptic potentiation at the CA3-CA1 region and 
ameliorates cognitive dysfunction in R6/1 mice (110).  
In HD, non-motor symptoms include sleep and circadian disturbances (reviewed in 
(261)). Interestingly, pathological up-regulation of cAMP/PKA signaling has been 
implicated in sleep and activity abnormalities in fly HD models. Elevated PKA activity in 
healthy flies produces patterns of sleep and activity similar to those found in flies 
expressing mutant huntingtin, whereas genetic reduction of PKA abolishes 
sleep/activity deficits, restores the homeostatic response and extends lifespan in HD 
flies. Remarkably, decreasing PKA also prevents immediate memory impairment in HD 
model flies (262). 
Summing up, aberrant PKA activity may be a general consequence of mutant 
huntingtin expression, and may underlie neuronal dysfunction in distinct brain areas 
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and several HD phenotypes. For instance, abnormalities in sleep and circadian rhythms 
have a negative impact on cognitive, emotional and psychiatric function. 
 
Deficient cGMP signaling 
The nitric oxide/soluble guanylyl cyclase/3',5'-cyclic guanosine monophosphate 
/cGMP-dependent protein kinase (NO/sGC/cGMP/cGK) signaling pathway has been 
widely implicated in synaptic plasticity, and in learning and memory in several brain 
regions, including the hippocampus (reviewed in (263)). Interestingly, neuronal NOS 
(nNOS) mRNA levels are decreased in the caudate of HD patients (264), and changes in 
nNOS protein levels also occur in the striatum and cortex of HD mouse models (265-
269). The study of the integrity of the nNOS/cGMP pathway in the hippocampus of HD 
mice, and of its potential contribution to hippocampal learning and memory deficits, 
has shown that both nNOS and cGMP levels are significantly reduced in the 
hippocampus of R6/1 mice, and that an acute post-training injection with sildenafil, a 
selective inhibitor of the cGMP-specific phosphodiesterase (PDE) 5 (270), increases 
cGMP levels and improves novel object recognition memory and passive avoidance 
learning (271). These data support the idea that decreased hippocampal cGMP levels 
contribute to cognitive dysfunction in R6/1 mice. Another study performed in the rat 
3-nitropropionic acid toxic model of HD shows that sildenafil treatment improves 
memory performance in the Morris water maze (272). Importantly, cGMP levels are 
also reduced in the hippocampus of HD patients (271). Thus, PDE5 inhibition may 
prove to be beneficial in ameliorating hippocampal-dependent cognitive deficits in HD.  
 
Transcriptional dysregulation: CREB and its co-activator CBP 
Transcriptional dysregulation has been shown in HD human brain, as well as in in vivo 
and in vitro disease models (241,273-278). Mutant huntingtin can cause transcriptional 
dysregulation by 1) sequestration of positive transcriptional regulators such as TATA-
binding protein (279), specificity protein-1 (280) or cAMP-response element binding 
protein (CREB) binding protein (CBP) (279,281); 2) loss of interaction with negative 
transcriptional regulators, such as the repressor element-1 transcription/neuron 
restrictive silencer factor (NRSE), resulting in REST/NRSF complex nuclear translocation 
and transcriptional repression of several neuronal-specific genes (282); and 3) 
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increasing ubiquitination and histone methylation, and reducing histone acetylation 
(283). 
CREB is a transcription factor that mediates stimulus-dependent changes in the 
expression of genes critical for neuronal survival, plasticity and growth (284-287). CREB 
activity is regulated by phosphorylation at serine 133 (Ser133) and at additional sites, 
as well as by association with CREB co-activators (288). Indeed, CREB phosphorylation 
at Ser133 facilitates the binding of the transcriptional co-activator CBP (289-292). The 
interaction between CREB and CBP, or other members of the transcriptional 
machinery, facilitates gene expression (291,293). In fact, CBP has emerged as a key 
regulator of CREB-mediated transcription by acting as a CREB transcriptional co-
activator (289,294,295) and as a histone acetyltransferase (HAT) to disrupt repressive 
chromatin structure and allow gene transcription (296-299). Expression of CREB-
related target genes is downregulated in several in vitro and in vivo models of HD 
(197,300,301). Moreover, mutant huntingtin interacts with CBP and blocks its HAT 
activity (302). Importantly, hypoacetylation of histone H3 is associated with 
downregulation of genes in R6/2 mice and knock-in cell lines (303). 
Activity-induced gene transcription is required for normal hippocampal synaptic 
plasticity and memory consolidation (47,304), and compelling evidence indicates that 
CREB is essential for activity-induced memory gene expression (305,306). Additionally, 
several studies show reduced chromatin acetylation and hippocampal LTP and long-
term memory (LTM) deficits in mouse models with compromised CBP activity (307-
312). In line with these data, CBP levels are reduced in the hippocampus of HD patients 
and Hdh
Q7/Q111
 mice in close correlation with the presence of spatial and recognition 
memory deficits (150). Moreover, reduced CBP levels in Hdh
Q7/Q111
 mice are associated 
with selective dysregulation of CREB/CBP-target genes related to memory and synaptic 
plasticity (c-fos, Nr4a2 and Arc) (150). Reduced CBP expression and/or activity have 
been associated with diminished H3 acetylation in mouse models of cognitive 
dysfunction (308,313,314). Consistently, decreased hippocampal CBP levels are 
paralleled by diminished H3 acetylation in Hdh
Q7/Q111
 mice, suggesting that lower CBP 
levels and decreased histone acetylation are responsible, at least in part, for memory 
dysfunction in HD (150). In agreement with studies showing that CBP HAT activity plays 
a crucial role in memory consolidation processes (313), and that trichostatin A (TSA), a 
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general histone deacetylase inhibitor, enhances hippocampal-dependent memory 
consolidation by increasing the expression of specific genes during memory 
consolidation (315), TSA reverses LTM impairment in Hdh
Q7/Q111
 mice, accompanied by 
increased levels of c-fos and Arc (150).  
 
Therapeutic strategies 
Currently, there is no known effective treatment for cognitive dysfunction in HD as so 
far clinical trials have tested traditional cognitive enhancers and anti-depressants 
without signs of efficacy (reviewed in (316)).  
The fact that in HD neuronal death does not occur until late stages of the disease 
suggests that neuronal dysfunction and abnormal synaptic plasticity occur earlier and 
are responsible for cognitive decline, which opens a window for therapeutic 
interventions. Moreover, targeting those early pathophysiological events is likely to 
provide better therapeutic outcomes than trying to prevent cell death once neurons 
are severely affected. As explained above, the presence of mutant huntingtin alters 
distinct cellular and molecular mechanisms, all of which can directly or indirectly 
impact on neuronal functioning, leading to synaptic and cognitive impairment. In this 
line, several genetic, pharmacological and non-pharmacological approaches have 
proved beneficial in HD models, not necessarily because they specifically target an 
altered mechanism or signaling cascade that participates in neuronal dysfunction 
leading to cognitive impairment, but because they improve the expression of receptor 
subunits, neurotrophic factors or other molecules involved in plasticity processes, 
and/or because they reduce the level of detrimental effectors. Next, we provide one 
such example. PDEs are the enzymes responsible for cAMP/cGMP degradation that 
through their different subcellular distribution allow compartmentalization and tight 
temporal and spatial control of cyclic nucleotide signaling (317). PDE inhibitors are 
increasingly being considered as cognitive enhancers (318-321), and the cognitive-
enhancing properties of a PDE10A inhibitor were recently examined in R6/1 mice. 
PDE10A, a cAMP/cGMP dual-substrate PDE, is enriched in nuclear fractions both in 
wild-type and R6/1 mouse hippocampus, without differences in its levels or 
intracellular distribution between genotypes. Chronic treatment with papaverine, a 
PDE10A inhibitor, improves spatial and object recognition memory in R6/1 mice, and 
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likely works through the activation of the PKA pathway, as the phosphorylation level of 
distinct cGK substrates is not modified in either genotype (322). These results appear 
to contradict the finding that increased PKA signaling in R6 mice hippocampus leads to 
hyperphosphorylation of PKA membrane targets implicated in synaptic plasticity and 
learning and memory, and to impairment of object recognition and spatial memory 
(139), while targeting aberrant PKA signaling improves hippocampal-dependent 
synaptic and cognitive function (110,139). Overall, these studies support the idea that 
hyperactivity of hippocampal PKA in HD mice is not a global event, but rather 
restricted to specific subcellular domains (139,322). In fact, the memory-enhancing 
effect of papaverine in R6/1 mice likely involves a partial, but significant, recovery of 
GluA1 phosphorylation levels together with increased CREB phosphorylation in the 
hippocampus (322). Thus, PDE10 might be a good therapeutic target to improve 
hippocampal cognitive impairment in HD. Remarkably, although striatal PDE10A levels 
are reduced well before motor symptom onset in HD (323), as confirmed by a study 
with the radioligand [18F] MNI-659A (324), PDE10 is being targeted for striatal 
dysfunction. Indeed, PDE10A inhibitors have attracted interest as potential novel 
pharmacotherapies for HD (325-329), with ongoing clinical trials (329). Nevertheless, in 
this section we chose to focus on those strategies with therapeutic potential for 
treating cognitive dysfunction in HD whose choice is justified by the identification of an 
affected pathway. 
Functional and morphological changes in the neocortex have been proposed as 
initial triggers of striatal pathology in HD. In this context, there is an early and specific 
reduction in cortical Kalirin-7 levels in HD mice, paralleled by early cortical dendritic 
spine alteration, impaired corticostriatal LTP and cognitive deficits (136). It is 
noteworthy that the number of cortical glutamatergic synapses in cultured HD neurons 
can be restored upon Kalirin-7 overexpression (136). Although the study of the impact 
of Kalirin-7 overexpression in adult HD mice is hampered by methodological 
limitations, the early loss of Kalirin-7 could contribute not only to decreased spine 
density, but probably also to altered corticostriatal synaptic transmission and cognitive 
deficits. In summary, the identification of Kalirin-7 downregulation at early HD stages 
and its role in modulating HD cortical excitatory synapses (136) allows us to 
hypothesize that cortical function could be restored by increasing the levels of Kalirin-
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7. Such increase could be the first step to prevent subsequent loss of corticostriatal 
connectivity, striatal dysfunction and, later, striatal neuronal degeneration.  
Concerning spine loss in MSNs, two mechanisms have been elucidated. One 
involves aberrant reactivation of juvenile GluN3A subunits, which promotes early and 
progressive dendritic spine pathology that likely underlies cognitive and motor 
impairment, and ultimately, neuronal death. In fact, lack of GluN3A ameliorates 
striatum-dependent cognitive and motor decline, and reduces striatal cell death in 
YAC128 mice (130), which has led to the proposal that GluN3A might be a good target 
for therapeutic approaches in HD (325). The other mechanism is associated with 
dysregulation of intracellular neuronal Ca
2+
 signaling, as enhanced nSOC has been 
shown to cause synaptic loss in HD MSNs (131). Interestingly, inhibition of nSOC with 
EVP4593 not only prevents spine loss in YAC128 MSNs, in vitro and in vivo (131), but 
also protects cultured HD MSNs against glutamate toxicity and improves motor 
symptoms in a fly model of HD (195), thus supporting the possibility that targeting 
nSOC could have a beneficial impact on HD. 
Another crucial regulator of synaptic plasticity and neuronal survival proposed as 
an excellent therapeutic target for treating the clinical hallmarks of HD is BDNF 
(164,165,330). However, BDNF administration has shown important methodological 
drawbacks in HD models (200), and several studies indicate that increasing BDNF levels 
only partially improves HD phenotype (129,141,331-333). Previous studies conducted 
by our group and others demonstrate reduced TrkB levels in patients and in different 
HD models (218-220). Together with the emerging evidence of imbalanced TrkB and 
p75
NTR
 expression/signaling in HD (135,201,220,221), this could contribute to the 
incomplete reversion of HD pathology by the administration of the neurotrophin.  
Although a general genetic reduction of p75
NTR
 levels in Hdh
Q7/Q111
 mouse brain 
does not prevent motor learning deficits or corticostriatal LTP abnormalities, the levels 
of DARPP-32, a striatal marker known to be reduced in HD mice from early stages 
(334), are reestablished (135). These results suggest that striatal neuronal dysfunction 
can be slightly ameliorated, but not prevented, by downregulation of aberrant p75
NTR
 
expression in Hdh
Q7/Q111
 brain. On the other hand, specific knockdown of striatal 
p75
NTR
 reverses corticostriatal LTP abnormalities in BACHD mice (201). In this context, 
it is important to note that p75
NTR
 levels are not altered in the cerebral cortex of HD 
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mice and patients (135,221), suggesting that decreased cortical p75
NTR
 levels in HD 
mice can be deleterious for synaptic plasticity and cognitive processes. Altered 
expression of TrkB and p75
NTR
 receptors disturbs BDNF-induced neuronal protection in 
a cellular HD model, and reduction of p75
NTR
 levels in corticostriatal slices of 
Hdh
Q111/Q111
 mice not only increases cell survival, but also prevents the cell death 
induced by BDNF (221). Therefore, targeting p75
NTR
 has the potential to improve 
corticostriatal plasticity and reduce cell death in HD. 
Besides impairment in corticostriatal connectivity, disturbances in hippocampal 
function contribute to HD memory deficits in middle disease stages. Thus, 
hippocampal dysfunction is an important hallmark of HD pathology, and 
preservation/restoration of hippocampal function could represent a promising 
alternative strategy to prevent memory loss in HD. In line with recent studies 
supporting a critical role for p75
NTR
 in hippocampal-dependent synaptic plasticity 
(223,224), normalization of hippocampal p75
NTR
 levels in distinct HD mouse models 
with genetic or pharmacological approaches rescues hippocampal synaptic plasticity, 
memory deficits and dendritic spine alterations, likely by normalization of the RhoA 
GTPase activity (107,135). Overall, this evidence suggests that antagonism of p75
NTR
 
could represent an excellent approach to restoring BDNF-mediated signaling in HD 
corticostriatal pathway, thereby restoring corticostriatal connectivity (201), 
ameliorating hippocampal synaptic dysfunction and memory deficits (135) and 
improving cell survival (221). An important consequence of these findings is that 
whereas TrkB is widely and robustly expressed in the adult brain, p75
NTR
 has a 
restricted tissue distribution, and its expression is developmentally downregulated in 
most parts of the brain, which makes the targeting of p75
NTR
 likely to have fewer side 
effects in HD patients. Remarkably, chronic administration of fingolimod (FTY720), an 
immunomodulatory drug used in the treatment of multiple sclerosis patients (335), 
ameliorates LTM deficits and dendritic spine loss in CA1 hippocampal neurons from 
R6/1 mice, and these effects are accompanied by normalization of p75
NTR
 levels and 
reduced astrogliosis in the hippocampus (107). Interestingly, chronic administration of 
FTY720 improves motor function, prolongs survival and reduces brain atrophy in R6/2 
mice, and these effects are accompanied by increased BDNF levels, strengthening of 
neuronal activity and connectivity, reduction of mutant huntingtin aggregates and 
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increased phosphorylation of mutant huntingtin in residues predicted to attenuate its 
toxicity (336). It would be useful to evaluate whether the normalization of p75
NTR
 
levels and reduction of astrogliosis reported in the hippocampus of FTY720-treated 
R6/1 mice (107) also occur in the striatum.  
Aberrant PKA signaling promotes hippocampal-dependent synaptic and memory 
impairment in HD mice (110,139). Notably, abnormal PKA signaling is also responsible 
for sleep disturbances in fly HD models, leading to the proposal of sleep and 
cAMP/PKA as prodromal indicators of disease, and therapeutic targets for intervention 
(262). Increased signaling through D1R and A2AR contributes to PKA overactivation 
and hippocampal-dependent synaptic and memory impairment in HD mice (110). 
Based on the finding that PKA activity is also increased in the hippocampus of HD 
patients (139), we propose that targeting D1R and A2AR might be a therapeutic 
approach to improve hippocampal-dependent cognitive function in HD. The combined 
antagonism of the two receptors normalizes striatal PKA activity, but does not 
ameliorate motor deficits (110), and inactivation of A2AR prevents working memory 
deficits in R6/2 mice, but does not modify motor dysfunction either (233). Actually, 
although striatal A2AR emerges as a novel target to fight against cognitive inflexibility, 
namely working memory impairment (233), this exciting therapeutic possibility needs 
to be carefully considered since targeting A2AR for HD motor symptoms remains 
largely controversial. Some studies demonstrate a neuroprotective effect of an A2AR 
antagonist in toxic models of HD, while others report no recovery from motor deficits 
or a delayed deterioration of motor performance after treatment with A2AR agonists 
in R6/2 mice (reviewed in (337-339)). Thus, targeting A2AR in HD is a puzzling issue, 
and the therapeutic window for A2AR antagonists might be restricted to the early 
phases of HD. Conversely, activation of A2AR normalizes synaptic activity in the 
striatum of symptomatic R6/2 mice, and may thus help to restore corticostriatal 
connectivity at later stages of the disease (232). 
In contrast to cAMP levels (110), hippocampal cGMP levels are reduced in HD mice 
(271). Since targeting the cGMP-specific PDE5 improves cGMP levels and ameliorates 
hippocampal-dependent learning and memory in R6/1 mice, and cGMP levels are also 
diminished in the hippocampus of HD patients (271), normalization of cGMP levels 
emerges as an approach to counteract deficits in hippocampal cognitive function in 
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HD. Given that the nNOS pathway is highly affected in the striatum and cortex too 
(265-269), it is tempting to speculate that targeting this pathway might also ameliorate 
corticostriatal dysfunction. So far, two studies have shown that the PDE5 inhibitor 
sildenafil protects against biochemical and behavioral abnormalities in the 3-
nitropropionic acid toxic model of HD (272,340), but whether sildenafil or other PDE5 
inhibitors improve corticostriatal connectivity, corticostriatal-dependent learning 
and/or motor dysfunction in genetic models of the disease remains to be addressed. It 
is noteworthy that cGMP can promote mitochondrial biogenesis and ATP synthesis 
(341), which is relevant because mitochondrial function is known to be compromised 
in HD (342). Furthermore, PDE5 inhibitors have emerged as a potential therapeutic 
strategy to improve not only cognitive function, but also to target neuroinflammation 
and neurodegeneration (reviewed in (343)), and thus they could be valuable multi-
purpose drugs in the context of HD. Moreover, it is expected that the use of PDE5 
inhibitors will prove to be of therapeutic interest because under physiological 
conditions transient elevations in striatal intracellular cGMP levels increase neuronal 
excitability and facilitate spontaneous and evoked corticostriatal transmission (344), 
which would improve connectivity in HD. Interestingly, intrastriatal infusion or 
systemic administration of the selective PDE10A inhibitor TP-10 increases the 
responsiveness of striatal MSNs to cortical input (345), and this effect depends on the 
NO-sGC-cGMP signaling cascade (346). Considering these findings and the reports on 
reduced nNOS mRNA in postmortem tissue from HD subjects (264) and in HD mouse 
models (265,269), it is likely that a combination of both PDE10A inhibitors and sGC 
activators will be useful to improve corticostriatal transmission in HD. 
As an alternative, or complementary, strategy to restore hippocampal function in 
HD at middle and advanced disease stages, we propose the modulation of CBP levels 
and/or activity. CBP levels are reduced in the hippocampus of Hdh
Q7/Q111
 mice, where 
they are accompanied by diminished histone 3 acetylation and spatial and recognition 
memory deficits (150). Since treatment with a general HDAC inhibitor reverses LTM 
impairment in Hdh
Q7/Q111
 mice, CBP loss of function may result in decreased memory-
related gene transcription and be responsible, at least in part, for the spatial and 
recognition memory deficits observed in Hdh
Q7/Q111
 mice (150). Remarkably, several 
studies suggest an important role of CBP loss of function in polyQ-dependent striatal 
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neurodegeneration in HD models (265,300,347-349). It is noteworthy that restoration 
of CBP striatal function by overexpression of CBP or by using HDAC inhibitors improves 
striatal atrophy and survival, as well as motor symptoms in HD models (350,351). 
Therefore, therapies aimed at increasing CBP levels and/or activity by using HDAC 
inhibitors hold the promise to be a good approach to prevent corticostriatal- and 
hippocampal-dependent dysfunction, motor symptoms and, ultimately, 
neurodegeneration. Remarkably, recent studies have found that HDACi 4b, a HDAC1/3 
inhibitor, has beneficial transgenerational effects in HD mice through altered DNA and 
histone methylation (352), while RGFP966, an inhibitor of HDAC3, improves motor 
deficits on rotarod and open field, accompanied by neuroprotective effects on striatal 
volume and decreased glial fibrillary acidic protein immunoreactivity in the striatum of 
N171-82Q mice (353). Therapies targeting transcriptional dysregulation in HD include 
sodium phenylbutyrate (phase I) and HDACi 4b (preclinical) (354). Even though 
research in this area is still at a preliminary stage, and crucial issues need to be 
addressed, such as the development of new potent and more selective HDAC 
inhibitors, with excellent blood-brain-barrier permeability, less cytotoxicity and 
reduced side effects, HDAC inhibitors show promise as a new avenue for therapeutic 
interventions in HD.  
 
Concluding remarks 
In summary, we have reviewed new evidence for early cortical and corticostriatal 
dysfunction in HD followed by hippocampal dysfunction, prior to the manifestation of 
motor symptoms, driving the search for novel therapeutic approaches to improve HD 
pathology at different disease stages. In particular, we propose that a first therapeutic 
intervention has to be focused on preserving/restoring corticostriatal connectivity, 
which would impact on intrinsic striatal function. In this context, given that reduced 
levels of Kalirin-7 are responsible, at least in part, for the early altered corticostriatal 
function, we propose the preservation/restoration of Kalirin-7 levels as an early 
therapeutic intervention to maintain functional cortical excitatory synapses. In the 
case of MSNs, recent evidence indicates that spine loss in YAC128 neurons is 
associated with reactivation of juvenile GluN3A. Although the downstream events are 
not fully characterized, these findings support the development of GluN3A-selective 
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antagonists and/or alternative therapeutic approaches to block abnormal GluN3A 
expression. Aberrant InsP3R1 activity leading to reduced ER Ca
2+
 levels and increased 
spine SOC are also implicated in MSNs spine loss, suggesting that targeting nSOC in 
MSNs might prove to be useful. Targeting the PKA pathway may ameliorate 
hippocampal plasticity and cognitive function in HD. To improve not only corticostriatal 
dysfunction, but also hippocampal-dependent deficits in HD, we propose 1) genetic or 
pharmacological inhibition of p75
NTR
 to preserve synaptic plasticity and cognitive 
function, as well as prevent striatal neuronal death, and 2) treatment with HDAC 
inhibitors that exhibit promising therapeutic effects in restoring memory and 
improving striatal survival and motor coordination at more advanced disease stages. 
Data obtained so far indicate that inhibition of PDE5 ameliorates hippocampal-
dependent learning and memory, but further studies are needed to address the 
therapeutic potential of targeting cGMP signaling using PDE inhibitors to improve 
corticostriatal dysfunction in HD. The use of PDE10A inhibitors will likely prove to be 
beneficial by improving both hippocampal and corticostriatal deficits in HD.  
 
 
REFERENCES 
 1.  Reiner,A., Albin,R.L., Anderson,K.D., D'Amato,C.J., Penney,J.B., Young,A.B. 
(1988) Differential loss of striatal projection neurons in Huntington disease. 
Proc. Natl. Acad. Sci. U. S. A, 85, 5733-5737. 
 2.  Vonsattel,J.P., DiFiglia,M. (1998) Huntington disease. J. Neuropathol. Exp. 
Neurol., 57, 369-384. 
 3.  Herndon,E.S., Hladik,C.L., Shang,P., Burns,D.K., Raisanen,J., White,C.L., III (2009) 
Neuroanatomic profile of polyglutamine immunoreactivity in Huntington 
disease brains. J. Neuropathol. Exp. Neurol., 68, 250-261. 
 4.  Ille,R., Schafer,A., Scharmuller,W., Enzinger,C., Schoggl,H., Kapfhammer,H.P., 
Schienle,A. (2011) Emotion recognition and experience in Huntington disease: a 
voxel-based morphometry study. J. Psychiatry Neurosci., 36, 383-390. 
 5.  Kassubek,J., Juengling,F.D., Kioschies,T., Henkel,K., Karitzky,J., Kramer,B., 
Ecker,D., Andrich,J., Saft,C., Kraus,P., et al. (2004) Topography of cerebral 
atrophy in early Huntington's disease: a voxel based morphometric MRI study. 
J. Neurol. Neurosurg. Psychiatry, 75, 213-220. 
Page 22 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
23 
 
 6.  Morton,A.J., Lagan,M.A., Skepper,J.N., Dunnett,S.B. (2000) Progressive 
formation of inclusions in the striatum and hippocampus of mice transgenic for 
the human Huntington's disease mutation. J. Neurocytol., 29, 679-702. 
 7.  Politis,M., Pavese,N., Tai,Y.F., Tabrizi,S.J., Barker,R.A., Piccini,P. (2008) 
Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain, 
131, 2860-2869. 
 8.  Rosas,H.D., Koroshetz,W.J., Chen,Y.I., Skeuse,C., Vangel,M., Cudkowicz,M.E., 
Caplan,K., Marek,K., Seidman,L.J., Makris,N., et al. (2003) Evidence for more 
widespread cerebral pathology in early HD: an MRI-based morphometric 
analysis. Neurology, 60, 1615-1620. 
 9.  Spargo,E., Everall,I.P., Lantos,P.L. (1993) Neuronal loss in the hippocampus in 
Huntington's disease: a comparison with HIV infection. J. Neurol. Neurosurg. 
Psychiatry, 56, 487-491. 
 10.  Caramins,M., Halliday,G., McCusker,E., Trent,R.J. (2003) Genetically confirmed 
clinical Huntington's disease with no observable cell loss. J. Neurol. Neurosurg. 
Psychiatry, 74, 968-970. 
 11.  Levine,M.S., Cepeda,C., Hickey,M.A., Fleming,S.M., Chesselet,M.F. (2004) 
Genetic mouse models of Huntington's and Parkinson's diseases: illuminating 
but imperfect. Trends Neurosci., 27, 691-697. 
 12.  Turmaine,M., Raza,A., Mahal,A., Mangiarini,L., Bates,G.P., Davies,S.W. (2000) 
Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's 
disease. Proc. Natl. Acad. Sci. U. S. A, 97, 8093-8097. 
 13.  Boll,T.J., Heaton,R., Reitan,R.M. (1974) Neuropsychological and emotional 
correlates of Huntington's chorea. J. Nerv. Ment. Dis., 158, 61-69. 
 14.  Stout,J.C., Glikmann-Johnston,Y., Andrews,S.C. (2016) Cognitive assessment 
strategies in Huntington's disease research. J. Neurosci. Methods, 265, 19-24. 
 15.  Dumas,E.M., van den Bogaard,S.J., Middelkoop,H.A., Roos,R.A. (2013) A review 
of cognition in Huntington's disease. Front Biosci. (Schol. Ed), 5, 1-18. 
 16.  Harrington,D.L., Smith,M.M., Zhang,Y., Carlozzi,N.E., Paulsen,J.S. (2012) 
Cognitive domains that predict time to diagnosis in prodromal Huntington 
disease. J. Neurol. Neurosurg. Psychiatry, 83, 612-619. 
 17.  Paulsen,J.S. (2011) Cognitive impairment in Huntington disease: diagnosis and 
treatment. Curr. Neurol. Neurosci. Rep., 11, 474-483. 
 18.  Stout,J.C., Paulsen,J.S., Queller,S., Solomon,A.C., Whitlock,K.B., Campbell,J.C., 
Carlozzi,N., Duff,K., Beglinger,L.J., Langbehn,D.R., et al. (2011) Neurocognitive 
signs in prodromal Huntington disease. Neuropsychology., 25, 1-14. 
Page 23 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
24 
 
 19.  Victorson,D., Carlozzi,N.E., Frank,S., Beaumont,J.L., Cheng,W., Gorin,B., 
Duh,M.S., Samuelson,D., Tulsky,D., Gutierrez,S., et al. (2014) Identifying motor, 
emotional-behavioral, and cognitive deficits that comprise the triad of HD 
symptoms from patient, caregiver, and provider perspectives. Tremor. Other 
Hyperkinet. Mov (N. Y.), 4, 224. 
 20.  Ferrante,R.J., Kowall,N.W., Richardson,E.P., Jr. (1991) Proliferative and 
degenerative changes in striatal spiny neurons in Huntington's disease: a 
combined study using the section-Golgi method and calbindin D28k 
immunocytochemistry. J. Neurosci., 11, 3877-3887. 
 21.  Vonsattel,J.P., Myers,R.H., Stevens,T.J., Ferrante,R.J., Bird,E.D., Richardson,E.P., 
Jr. (1985) Neuropathological classification of Huntington's disease. J. 
Neuropathol. Exp. Neurol., 44, 559-577. 
 22.  Estrada-Sanchez,A.M., Rebec,G.V. (2013) Role of cerebral cortex in the 
neuropathology of Huntington's disease. Front Neural Circuits., 7, 19. 
 23.  Ho,A.K., Sahakian,B.J., Brown,R.G., Barker,R.A., Hodges,J.R., Ane,M.N., 
Snowden,J., Thompson,J., Esmonde,T., Gentry,R., et al. (2003) Profile of 
cognitive progression in early Huntington's disease. Neurology, 61, 1702-1706. 
 24.  Lawrence,A.D., Weeks,R.A., Brooks,D.J., Andrews,T.C., Watkins,L.H., 
Harding,A.E., Robbins,T.W., Sahakian,B.J. (1998) The relationship between 
striatal dopamine receptor binding and cognitive performance in Huntington's 
disease. Brain, 121 (Pt 7), 1343-1355. 
 25.  Hahn-Barma,V., Deweer,B., Durr,A., Dode,C., Feingold,J., Pillon,B., Agid,Y., 
Brice,A., Dubois,B. (1998) Are cognitive changes the first symptoms of 
Huntington's disease? A study of gene carriers. J. Neurol. Neurosurg. Psychiatry, 
64, 172-177. 
 26.  Paulsen,J.S., Zhao,H., Stout,J.C., Brinkman,R.R., Guttman,M., Ross,C.A., 
Como,P., Manning,C., Hayden,M.R., Shoulson,I. (2001) Clinical markers of early 
disease in persons near onset of Huntington's disease. Neurology, 57, 658-662. 
 27.  Lawrence,A.D., Hodges,J.R., Rosser,A.E., Kershaw,A., ffrench-Constant,C., 
Rubinsztein,D.C., Robbins,T.W., Sahakian,B.J. (1998) Evidence for specific 
cognitive deficits in preclinical Huntington's disease. Brain, 121 (Pt 7), 1329-
1341. 
 28.  Rosenberg,N.K., Sorensen,S.A., Christensen,A.L. (1995) Neuropsychological 
characteristics of Huntington's disease carriers: a double blind study. J. Med. 
Genet., 32, 600-604. 
 29.  Schneider,S.A., Wilkinson,L., Bhatia,K.P., Henley,S.M., Rothwell,J.C., Tabrizi,S.J., 
Jahanshahi,M. (2010) Abnormal explicit but normal implicit sequence learning 
in premanifest and early Huntington's disease. Mov Disord., 25, 1343-1349. 
Page 24 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
25 
 
 30.  Poudel,G.R., Egan,G.F., Churchyard,A., Chua,P., Stout,J.C., Georgiou-
Karistianis,N. (2014) Abnormal synchrony of resting state networks in 
premanifest and symptomatic Huntington disease: the IMAGE-HD study. J. 
Psychiatry Neurosci., 39, 87-96. 
 31.  Poudel,G.R., Stout,J.C., Dominguez,D.J., Salmon,L., Churchyard,A., Chua,P., 
Georgiou-Karistianis,N., Egan,G.F. (2014) White matter connectivity reflects 
clinical and cognitive status in Huntington's disease. Neurobiol. Dis., 65, 180-
187. 
 32.  Unschuld,P.G., Joel,S.E., Liu,X., Shanahan,M., Margolis,R.L., Biglan,K.M., 
Bassett,S.S., Schretlen,D.J., Redgrave,G.W., van Zijl,P.C., et al. (2012) Impaired 
cortico-striatal functional connectivity in prodromal Huntington's Disease. 
Neurosci. Lett., 514, 204-209. 
 33.  Kim,J.S., Reading,S.A., Brashers-Krug,T., Calhoun,V.D., Ross,C.A., Pearlson,G.D. 
(2004) Functional MRI study of a serial reaction time task in Huntington's 
disease. Psychiatry Res., 131, 23-30. 
 34.  Backman,L., Robins-Wahlin,T.B., Lundin,A., Ginovart,N., Farde,L. (1997) 
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET 
markers and brain volumes. Brain, 120 (Pt 12), 2207-2217. 
 35.  Lemiere,J., Decruyenaere,M., Evers-Kiebooms,G., Vandenbussche,E., Dom,R. 
(2004) Cognitive changes in patients with Huntington's disease (HD) and 
asymptomatic carriers of the HD mutation--a longitudinal follow-up study. J. 
Neurol., 251, 935-942. 
 36.  Paulsen,J.S., Butters,N., Sadek,J.R., Johnson,S.A., Salmon,D.P., Swerdlow,N.R., 
Swenson,M.R. (1995) Distinct cognitive profiles of cortical and subcortical 
dementia in advanced illness. Neurology, 45, 951-956. 
 37.  Zakzanis,K.K. (1998) The subcortical dementia of Huntington's disease. J. Clin. 
Exp. Neuropsychol., 20, 565-578. 
 38.  DiFiglia,M., Sapp,E., Chase,K.O., Davies,S.W., Bates,G.P., Vonsattel,J.P., 
Aronin,N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions 
and dystrophic neurites in brain. Science, 277, 1990-1993. 
 39.  Sapp,E., Schwarz,C., Chase,K., Bhide,P.G., Young,A.B., Penney,J., Vonsattel,J.P., 
Aronin,N., DiFiglia,M. (1997) Huntingtin localization in brains of normal and 
Huntington's disease patients. Ann. Neurol., 42, 604-612. 
 40.  Sapp,E., Penney,J., Young,A., Aronin,N., Vonsattel,J.P., DiFiglia,M. (1999) Axonal 
transport of N-terminal huntingtin suggests early pathology of corticostriatal 
projections in Huntington disease. J. Neuropathol. Exp. Neurol., 58, 165-173. 
 41.  Rosas,H.D., Lee,S.Y., Bender,A.C., Zaleta,A.K., Vangel,M., Yu,P., Fischl,B., 
Pappu,V., Onorato,C., Cha,J.H., et al. (2010) Altered white matter 
Page 25 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
26 
 
microstructure in the corpus callosum in Huntington's disease: implications for 
cortical "disconnection". Neuroimage., 49, 2995-3004. 
 42.  Bliss,T.V., Collingridge,G.L. (1993) A synaptic model of memory: long-term 
potentiation in the hippocampus. Nature, 361, 31-39. 
 43.  Burgess,N., Maguire,E.A., O'Keefe,J. (2002) The human hippocampus and 
spatial and episodic memory. Neuron, 35, 625-641. 
 44.  Eichenbaum,H. (2001) The hippocampus and declarative memory: cognitive 
mechanisms and neural codes. Behav. Brain Res., 127, 199-207. 
 45.  Gruart,A., Delgado-Garcia,J.M. (2007) Activity-dependent changes of the 
hippocampal CA3-CA1 synapse during the acquisition of associative learning in 
conscious mice. Genes Brain Behav., 6 Suppl 1, 24-31. 
 46.  Kandel,E.R., Pittenger,C. (1999) The past, the future and the biology of memory 
storage. Philos. Trans. R. Soc. Lond B Biol. Sci., 354, 2027-2052. 
 47.  Kandel,E.R. (2001) The molecular biology of memory storage: a dialogue 
between genes and synapses. Science, 294, 1030-1038. 
 48.  Kessels,R.P., de Haan,E.H., Kappelle,L.J., Postma,A. (2001) Varieties of human 
spatial memory: a meta-analysis on the effects of hippocampal lesions. Brain 
Res. Brain Res. Rev., 35, 295-303. 
 49.  Thierry,A.M., Gioanni,Y., Degenetais,E., Glowinski,J. (2000) Hippocampo-
prefrontal cortex pathway: anatomical and electrophysiological characteristics. 
Hippocampus, 10, 411-419. 
 50.  Clarke,J.R., Cammarota,M., Gruart,A., Izquierdo,I., Delgado-Garcia,J.M. (2010) 
Plastic modifications induced by object recognition memory processing. Proc. 
Natl. Acad. Sci. U. S. A, 107, 2652-2657. 
 51.  Eichenbaum,H. (2004) Hippocampus: cognitive processes and neural 
representations that underlie declarative memory. Neuron, 44, 109-120. 
 52.  Montaldi,D., Mayes,A.R. (2010) The role of recollection and familiarity in the 
functional differentiation of the medial temporal lobes. Hippocampus, 20, 
1291-1314. 
 53.  Berrios,G.E., Wagle,A.C., Markova,I.S., Wagle,S.A., Rosser,A., Hodges,J.R. (2002) 
Psychiatric symptoms in neurologically asymptomatic Huntington's disease 
gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr. 
Scand., 105, 224-230. 
 54.  Begeti,F., Schwab,L.C., Mason,S.L., Barker,R.A. (2016) Hippocampal dysfunction 
defines disease onset in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 
Page 26 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
27 
 
 55.  Lawrence,A.D., Watkins,L.H., Sahakian,B.J., Hodges,J.R., Robbins,T.W. (2000) 
Visual object and visuospatial cognition in Huntington's disease: implications 
for information processing in corticostriatal circuits. Brain, 123 (Pt 7), 1349-
1364. 
 56.  Montoya,A., Pelletier,M., Menear,M., Duplessis,E., Richer,F., Lepage,M. (2006) 
Episodic memory impairment in Huntington's disease: a meta-analysis. 
Neuropsychologia, 44, 1984-1994. 
 57.  Voermans,N.C., Petersson,K.M., Daudey,L., Weber,B., Van Spaendonck,K.P., 
Kremer,H.P., Fernandez,G. (2004) Interaction between the human 
hippocampus and the caudate nucleus during route recognition. Neuron, 43, 
427-435. 
 58.  Papoutsi,M., Labuschagne,I., Tabrizi,S.J., Stout,J.C. (2014) The cognitive burden 
in Huntington's disease: pathology, phenotype, and mechanisms of 
compensation. Mov Disord., 29, 673-683. 
 59.  The Huntington's Disease Collaborative Research Group.  (1993) A novel gene 
containing a trinucleotide repeat that is expanded and unstable on 
Huntington's disease chromosomes. Cell, 72, 971-983. 
 60.  Cepeda,C., Cummings,D.M., Andre,V.M., Holley,S.M., Levine,M.S. (2010) 
Genetic mouse models of Huntington's disease: focus on electrophysiological 
mechanisms. ASN. Neuro., 2, e00033. 
 61.  Chang,R., Liu,X., Li,S., Li,X.J. (2015) Transgenic animal models for study of the 
pathogenesis of Huntington's disease and therapy. Drug Des Devel. Ther., 9, 
2179-2188. 
 62.  Menalled,L., Brunner,D. (2014) Animal models of Huntington's disease for 
translation to the clinic: best practices. Mov Disord., 29, 1375-1390. 
 63.  Plotkin,J.L., Surmeier,D.J. (2015) Corticostriatal synaptic adaptations in 
Huntington's disease. Curr. Opin. Neurobiol., 33, 53-62. 
 64.  Behr,J., Wozny,C., Fidzinski,P., Schmitz,D. (2009) Synaptic plasticity in the 
subiculum. Prog. Neurobiol., 89, 334-342. 
 65.  Gladding,C.M., Fitzjohn,S.M., Molnar,E. (2009) Metabotropic glutamate 
receptor-mediated long-term depression: molecular mechanisms. Pharmacol. 
Rev., 61, 395-412. 
 66.  Lynch,M.A. (2004) Long-term potentiation and memory. Physiol Rev., 84, 87-
136. 
 67.  Cepeda,C., Wu,N., Andre,V.M., Cummings,D.M., Levine,M.S. (2007) The 
corticostriatal pathway in Huntington's disease. Prog. Neurobiol., 81, 253-271. 
Page 27 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
28 
 
 68.  Fan,M.M., Raymond,L.A. (2007) N-methyl-D-aspartate (NMDA) receptor 
function and excitotoxicity in Huntington's disease. Prog. Neurobiol., 81, 272-
293. 
 69.  Li,J.Y., Plomann,M., Brundin,P. (2003) Huntington's disease: a synaptopathy? 
Trends Mol. Med., 9, 414-420. 
 70.  Nithianantharajah,J., Hannan,A.J. (2013) Dysregulation of synaptic proteins, 
dendritic spine abnormalities and pathological plasticity of synapses as 
experience-dependent mediators of cognitive and psychiatric symptoms in 
Huntington's disease. Neuroscience, 251, 66-74. 
 71.  Raymond,L.A., Andre,V.M., Cepeda,C., Gladding,C.M., Milnerwood,A.J., 
Levine,M.S. (2011) Pathophysiology of Huntington's disease: time-dependent 
alterations in synaptic and receptor function. Neuroscience, 198, 252-273. 
 72.  Buren,C., Parsons,M.P., Smith-Dijak,A., Raymond,L.A. (2016) Impaired 
development of cortico-striatal synaptic connectivity in a cell culture model of 
Huntington's disease. Neurobiol. Dis., 87, 80-90. 
 73.  Gu,X., Li,C., Wei,W., Lo,V., Gong,S., Li,S.H., Iwasato,T., Itohara,S., Li,X.J., 
Mody,I., et al. (2005) Pathological cell-cell interactions elicited by a 
neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis 
in HD mice. Neuron, 46, 433-444. 
 74.  Gu,X., Andre,V.M., Cepeda,C., Li,S.H., Li,X.J., Levine,M.S., Yang,X.W. (2007) 
Pathological cell-cell interactions are necessary for striatal pathogenesis in a 
conditional mouse model of Huntington's disease. Mol. Neurodegener., 2, 8. 
 75.  Wang,N., Gray,M., Lu,X.H., Cantle,J.P., Holley,S.M., Greiner,E., Gu,X., 
Shirasaki,D., Cepeda,C., Li,Y., et al. (2014) Neuronal targets for reducing mutant 
huntingtin expression to ameliorate disease in a mouse model of Huntington's 
disease. Nat. Med., 20, 536-541. 
 76.  Estrada-Sanchez,A.M., Burroughs,C.L., Cavaliere,S., Barton,S.J., Chen,S., 
Yang,X.W., Rebec,G.V. (2015) Cortical efferents lacking mutant huntingtin 
improve striatal neuronal activity and behavior in a conditional mouse model of 
Huntington's disease. J. Neurosci., 35, 4440-4451. 
 77.  Bates,G.P., Mangiarini,L., Mahal,A., Davies,S.W. (1997) Transgenic models of 
Huntington's disease. Hum. Mol. Genet., 6, 1633-1637. 
 78.  Davies,S.W., Turmaine,M., Cozens,B.A., DiFiglia,M., Sharp,A.H., Ross,C.A., 
Scherzinger,E., Wanker,E.E., Mangiarini,L., Bates,G.P. (1997) Formation of 
neuronal intranuclear inclusions underlies the neurological dysfunction in mice 
transgenic for the HD mutation. Cell, 90, 537-548. 
 79.  Mangiarini,L., Sathasivam,K., Seller,M., Cozens,B., Harper,A., Hetherington,C., 
Lawton,M., Trottier,Y., Lehrach,H., Davies,S.W., Bates,G.P. (1996) Exon 1 of the 
Page 28 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
29 
 
HD gene with an expanded CAG repeat is sufficient to cause a progressive 
neurological phenotype in transgenic mice. Cell, 87, 493-506. 
 80.  Meade,C.A., Deng,Y.P., Fusco,F.R., Del,M.N., Hersch,S., Goldowitz,D., Reiner,A. 
(2002) Cellular localization and development of neuronal intranuclear 
inclusions in striatal and cortical neurons in R6/2 transgenic mice. J. Comp 
Neurol., 449, 241-269. 
 81.  Schilling,G., Becher,M.W., Sharp,A.H., Jinnah,H.A., Duan,K., Kotzuk,J.A., 
Slunt,H.H., Ratovitski,T., Cooper,J.K., Jenkins,N.A., et al. (1999) Intranuclear 
inclusions and neuritic aggregates in transgenic mice expressing a mutant N-
terminal fragment of huntingtin. Hum. Mol. Genet., 8, 397-407. 
 82.  Yamamoto,A., Lucas,J.J., Hen,R. (2000) Reversal of neuropathology and motor 
dysfunction in a conditional model of Huntington's disease. Cell, 101, 57-66. 
 83.  Hodgson,J.G., Agopyan,N., Gutekunst,C.A., Leavitt,B.R., LePiane,F., Singaraja,R., 
Smith,D.J., Bissada,N., McCutcheon,K., Nasir,J., et al. (1999) A YAC mouse 
model for Huntington's disease with full-length mutant huntingtin, cytoplasmic 
toxicity, and selective striatal neurodegeneration. Neuron, 23, 181-192. 
 84.  Seo,H., Kim,W., Isacson,O. (2008) Compensatory changes in the ubiquitin-
proteasome system, brain-derived neurotrophic factor and mitochondrial 
complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's 
disease patients. Hum. Mol. Genet., 17, 3144-3153. 
 85.  van Raamsdonk,J.M., Warby,S.C., Hayden,M.R. (2007) Selective degeneration in 
YAC mouse models of Huntington disease. Brain Res. Bull., 72, 124-131. 
 86.  Pouladi,M.A., Xie,Y., Skotte,N.H., Ehrnhoefer,D.E., Graham,R.K., Kim,J.E., 
Bissada,N., Yang,X.W., Paganetti,P., Friedlander,R.M., et al. (2010) Full-length 
huntingtin levels modulate body weight by influencing insulin-like growth 
factor 1 expression. Hum. Mol. Genet., 19, 1528-1538. 
 87.  Pouladi,M.A., Stanek,L.M., Xie,Y., Franciosi,S., Southwell,A.L., Deng,Y., 
Butland,S., Zhang,W., Cheng,S.H., Shihabuddin,L.S., Hayden,M.R. (2012) 
Marked differences in neurochemistry and aggregates despite similar 
behavioural and neuropathological features of Huntington disease in the full-
length BACHD and YAC128 mice. Hum. Mol. Genet., 21, 2219-2232. 
 88.  Slow,E.J., van,R.J., Rogers,D., Coleman,S.H., Graham,R.K., Deng,Y., Oh,R., 
Bissada,N., Hossain,S.M., Yang,Y.Z., et al. (2003) Selective striatal neuronal loss 
in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 12, 1555-
1567. 
 89.  van Raamsdonk,J.M., Murphy,Z., Slow,E.J., Leavitt,B.R., Hayden,M.R. (2005) 
Selective degeneration and nuclear localization of mutant huntingtin in the 
YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 14, 3823-3835. 
Page 29 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
30 
 
 90.  van Raamsdonk,J.M., Pearson,J., Murphy,Z., Hayden,M.R., Leavitt,B.R. (2006) 
Wild-type huntingtin ameliorates striatal neuronal atrophy but does not 
prevent other abnormalities in the YAC128 mouse model of Huntington 
disease. BMC. Neurosci., 7, 80. 
 91.  Gray,M., Shirasaki,D.I., Cepeda,C., Andre,V.M., Wilburn,B., Lu,X.H., Tao,J., 
Yamazaki,I., Li,S.H., Sun,Y.E., et al. (2008) Full-length human mutant huntingtin 
with a stable polyglutamine repeat can elicit progressive and selective 
neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182-6195. 
 92.  Hult,L.S., Nilsson,N., Soylu,R., Kirik,D., Petersen,A. (2013) Hypothalamic 
expression of mutant huntingtin contributes to the development of depressive-
like behavior in the BAC transgenic mouse model of Huntington's disease. Hum. 
Mol. Genet., 22, 3485-3497. 
 93.  Fossale,E., Wheeler,V.C., Vrbanac,V., Lebel,L.A., Teed,A., Mysore,J.S., 
Gusella,J.F., MacDonald,M.E., Persichetti,F. (2002) Identification of a 
presymptomatic molecular phenotype in Hdh CAG knock-in mice. Hum. Mol. 
Genet., 11, 2233-2241. 
 94.  Wheeler,V.C., Auerbach,W., White,J.K., Srinidhi,J., Auerbach,A., Ryan,A., 
Duyao,M.P., Vrbanac,V., Weaver,M., Gusella,J.F., et al. (1999) Length-
dependent gametic CAG repeat instability in the Huntington's disease knock-in 
mouse. Hum. Mol. Genet., 8, 115-122. 
 95.  Wheeler,V.C., White,J.K., Gutekunst,C.A., Vrbanac,V., Weaver,M., Li,X.J., Li,S.H., 
Yi,H., Vonsattel,J.P., Gusella,J.F., et al. (2000) Long glutamine tracts cause 
nuclear localization of a novel form of huntingtin in medium spiny striatal 
neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet., 9, 503-513. 
 96.  Wheeler,V.C., Gutekunst,C.A., Vrbanac,V., Lebel,L.A., Schilling,G., Hersch,S., 
Friedlander,R.M., Gusella,J.F., Vonsattel,J.P., Borchelt,D.R., MacDonald,M.E. 
(2002) Early phenotypes that presage late-onset neurodegenerative disease 
allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet., 11, 
633-640. 
 97.  Wheeler,V.C., Lebel,L.A., Vrbanac,V., Teed,A., te,R.H., MacDonald,M.E. (2003) 
Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) 
striatum. Hum. Mol. Genet., 12, 273-281. 
 98.  Menalled,L.B., Sison,J.D., Dragatsis,I., Zeitlin,S., Chesselet,M.F. (2003) Time 
course of early motor and neuropathological anomalies in a knock-in mouse 
model of Huntington's disease with 140 CAG repeats. J. Comp Neurol., 465, 11-
26. 
 99.  Gafni,J., Hermel,E., Young,J.E., Wellington,C.L., Hayden,M.R., Ellerby,L.M. 
(2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: 
accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem., 279, 
20211-20220. 
Page 30 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
31 
 
 100.  Lin,C.H., Tallaksen-Greene,S., Chien,W.M., Cearley,J.A., Jackson,W.S., 
Crouse,A.B., Ren,S., Li,X.J., Albin,R.L., Detloff,P.J. (2001) Neurological 
abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. 
Genet., 10, 137-144. 
 101.  Yu,Z.X., Li,S.H., Evans,J., Pillarisetti,A., Li,H., Li,X.J. (2003) Mutant huntingtin 
causes context-dependent neurodegeneration in mice with Huntington's 
disease. J. Neurosci., 23, 2193-2202. 
 102.  Brooks,S.P., Janghra,N., Workman,V.L., Bayram-Weston,Z., Jones,L., 
Dunnett,S.B. (2012) Longitudinal analysis of the behavioural phenotype in R6/1 
(C57BL/6J) Huntington's disease transgenic mice. Brain Res. Bull., 88, 94-103. 
 103.  Cepeda,C., Starling,A.J., Wu,N., Nguyen,O.K., Uzgil,B., Soda,T., Andre,V.M., 
Ariano,M.A., Levine,M.S. (2004) Increased GABAergic function in mouse models 
of Huntington's disease: reversal by BDNF. J. Neurosci. Res., 78, 855-867. 
 104.  Cummings,D.M., Andre,V.M., Uzgil,B.O., Gee,S.M., Fisher,Y.E., Cepeda,C., 
Levine,M.S. (2009) Alterations in cortical excitation and inhibition in genetic 
mouse models of Huntington's disease. J. Neurosci., 29, 10371-10386. 
 105.  Cybulska-Klosowicz,A., Mazarakis,N.K., van,D.A., Blakemore,C., Hannan,A.J., 
Kossut,M. (2004) Impaired learning-dependent cortical plasticity in 
Huntington's disease transgenic mice. Neurobiol. Dis., 17, 427-434. 
 106.  Giralt,A., Rodrigo,T., Martin,E.D., Gonzalez,J.R., Mila,M., Cena,V., Dierssen,M., 
Canals,J.M., Alberch,J. (2009) Brain-derived neurotrophic factor modulates the 
severity of cognitive alterations induced by mutant huntingtin: involvement of 
phospholipaseCgamma activity and glutamate receptor expression. 
Neuroscience, 158, 1234-1250. 
 107.  Miguez,A., Garcia-Diaz,B.G., Brito,V., Straccia,M., Giralt,A., Gines,S., Canals,J.M., 
Alberch,J. (2015) Fingolimod (FTY720) enhances hippocampal synaptic plasticity 
and memory in Huntington's disease by preventing p75NTR up-regulation and 
astrocyte-mediated inflammation. Hum. Mol. Genet., 24, 4958-4970. 
 108.  Milnerwood,A.J., Cummings,D.M., Dallerac,G.M., Brown,J.Y., Vatsavayai,S.C., 
Hirst,M.C., Rezaie,P., Murphy,K.P. (2006) Early development of aberrant 
synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet., 
15, 1690-1703. 
 109.  Spires,T.L., Grote,H.E., Garry,S., Cordery,P.M., van,D.A., Blakemore,C., 
Hannan,A.J. (2004) Dendritic spine pathology and deficits in experience-
dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. 
Eur. J. Neurosci., 19, 2799-2807. 
 110.  Tyebji,S., Saavedra,A., Canas,P.M., Pliassova,A., Delgado-Garcia,J.M., Alberch,J., 
Cunha,R.A., Gruart,A., Perez-Navarro,E. (2015) Hyperactivation of D1 and A2A 
Page 31 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
32 
 
receptors contributes to cognitive dysfunction in Huntington's disease. 
Neurobiol. Dis., 74, 41-57. 
 111.  Cummings,D.M., Milnerwood,A.J., Dallerac,G.M., Waights,V., Brown,J.Y., 
Vatsavayai,S.C., Hirst,M.C., Murphy,K.P. (2006) Aberrant cortical synaptic 
plasticity and dopaminergic dysfunction in a mouse model of Huntington's 
disease. Hum. Mol. Genet., 15, 2856-2868. 
 112.  Cummings,D.M., Milnerwood,A.J., Dallerac,G.M., Vatsavayai,S.C., Hirst,M.C., 
Murphy,K.P. (2007) Abnormal cortical synaptic plasticity in a mouse model of 
Huntington's disease. Brain Res. Bull., 72, 103-107. 
 113.  Andre,V.M., Cepeda,C., Venegas,A., Gomez,Y., Levine,M.S. (2006) Altered 
cortical glutamate receptor function in the R6/2 model of Huntington's disease. 
J. Neurophysiol., 95, 2108-2119. 
 114.  Cepeda,C., Hurst,R.S., Calvert,C.R., Hernandez-Echeagaray,E., Nguyen,O.K., 
Jocoy,E., Christian,L.J., Ariano,M.A., Levine,M.S. (2003) Transient and 
progressive electrophysiological alterations in the corticostriatal pathway in a 
mouse model of Huntington's disease. J. Neurosci., 23, 961-969. 
 115.  Cummings,D.M., Cepeda,C., Levine,M.S. (2010) Alterations in striatal synaptic 
transmission are consistent across genetic mouse models of Huntington's 
disease. ASN. Neuro., 2, e00036. 
 116.  Heck,N., Betuing,S., Vanhoutte,P., Caboche,J. (2012) A deconvolution method 
to improve automated 3D-analysis of dendritic spines: application to a mouse 
model of Huntington's disease. Brain Struct. Funct., 217, 421-434. 
 117.  Hong,S.L., Cossyleon,D., Hussain,W.A., Walker,L.J., Barton,S.J., Rebec,G.V. 
(2012) Dysfunctional behavioral modulation of corticostriatal communication in 
the R6/2 mouse model of Huntington's disease. PLoS. One., 7, e47026. 
 118.  Klapstein,G.J., Fisher,R.S., Zanjani,H., Cepeda,C., Jokel,E.S., Chesselet,M.F., 
Levine,M.S. (2001) Electrophysiological and morphological changes in striatal 
spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol., 
86, 2667-2677. 
 119.  Laforet,G.A., Sapp,E., Chase,K., McIntyre,C., Boyce,F.M., Campbell,M., 
Cadigan,B.A., Warzecki,L., Tagle,D.A., Reddy,P.H., et al. (2001) Changes in 
cortical and striatal neurons predict behavioral and electrophysiological 
abnormalities in a transgenic murine model of Huntington's disease. J. 
Neurosci., 21, 9112-9123. 
 120.  Lione,L.A., Carter,R.J., Hunt,M.J., Bates,G.P., Morton,A.J., Dunnett,S.B. (1999) 
Selective discrimination learning impairments in mice expressing the human 
Huntington's disease mutation. J. Neurosci., 19, 10428-10437. 
Page 32 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
33 
 
 121.  Murmu,R.P., Li,W., Holtmaat,A., Li,J.Y. (2013) Dendritic spine instability leads to 
progressive neocortical spine loss in a mouse model of Huntington's disease. J. 
Neurosci., 33, 12997-13009. 
 122.  Murphy,K.P., Carter,R.J., Lione,L.A., Mangiarini,L., Mahal,A., Bates,G.P., 
Dunnett,S.B., Morton,A.J. (2000) Abnormal synaptic plasticity and impaired 
spatial cognition in mice transgenic for exon 1 of the human Huntington's 
disease mutation. J. Neurosci., 20, 5115-5123. 
 123.  Rossi,S., Prosperetti,C., Picconi,B., De,C., V, Mataluni,G., Bernardi,G., 
Calabresi,P., Centonze,D. (2006) Deficits of glutamate transmission in the 
striatum of toxic and genetic models of Huntington's disease. Neurosci. Lett., 
410, 6-10. 
 124.  Li,L., Fan,M., Icton,C.D., Chen,N., Leavitt,B.R., Hayden,M.R., Murphy,T.H., 
Raymond,L.A. (2003) Role of NR2B-type NMDA receptors in selective 
neurodegeneration in Huntington disease. Neurobiol. Aging, 24, 1113-1121. 
 125.  Li,L., Murphy,T.H., Hayden,M.R., Raymond,L.A. (2004) Enhanced striatal NR2B-
containing N-methyl-D-aspartate receptor-mediated synaptic currents in a 
mouse model of Huntington disease. J. Neurophysiol., 92, 2738-2746. 
 126.  Milnerwood,A.J., Raymond,L.A. (2007) Corticostriatal synaptic function in 
mouse models of Huntington's disease: early effects of huntingtin repeat length 
and protein load. J. Physiol, 585, 817-831. 
 127.  Ghilan,M., Bostrom,C.A., Hryciw,B.N., Simpson,J.M., Christie,B.R., Gil-
Mohapel,J. (2014) YAC128 Huntington's disease transgenic mice show 
enhanced short-term hippocampal synaptic plasticity early in the course of the 
disease. Brain Res., 1581, 117-128. 
 128.  Joshi,P.R., Wu,N.P., Andre,V.M., Cummings,D.M., Cepeda,C., Joyce,J.A., 
Carroll,J.B., Leavitt,B.R., Hayden,M.R., Levine,M.S., Bamford,N.S. (2009) Age-
dependent alterations of corticostriatal activity in the YAC128 mouse model of 
Huntington disease. J. Neurosci., 29, 2414-2427. 
 129.  Xie,Y., Hayden,M.R., Xu,B. (2010) BDNF overexpression in the forebrain rescues 
Huntington's disease phenotypes in YAC128 mice. J. Neurosci., 30, 14708-
14718. 
 130.  Marco,S., Giralt,A., Petrovic,M.M., Pouladi,M.A., Martinez-Turrillas,R., 
Martinez-Hernandez,J., Kaltenbach,L.S., Torres-Peraza,J., Graham,R.K., 
Watanabe,M., et al. (2013) Suppressing aberrant GluN3A expression rescues 
synaptic and behavioral impairments in Huntington's disease models. Nat. 
Med., 19, 1030-1038. 
 131.  Wu,J., Ryskamp,D.A., Liang,X., Egorova,P., Zakharova,O., Hung,G., 
Bezprozvanny,I. (2016) Enhanced store-operated calcium entry leads to striatal 
synaptic loss in a Huntington's disease mouse model. J. Neurosci., 36, 125-141. 
Page 33 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
34 
 
 132.  Rocher,A.B., Gubellini,P., Merienne,N., Boussicault,L., Petit,F., Gipchtein,P., 
Jan,C., Hantraye,P., Brouillet,E., Bonvento,G. (2016) Synaptic scaling up in 
medium spiny neurons of aged BACHD mice: A slow-progression model of 
Huntington's disease. Neurobiol. Dis., 86, 131-139. 
 133.  Spampanato,J., Gu,X., Yang,X.W., Mody,I. (2008) Progressive synaptic 
pathology of motor cortical neurons in a BAC transgenic mouse model of 
Huntington's disease. Neuroscience, 157, 606-620. 
 134.  Lynch,G., Kramar,E.A., Rex,C.S., Jia,Y., Chappas,D., Gall,C.M., Simmons,D.A. 
(2007) Brain-derived neurotrophic factor restores synaptic plasticity in a knock-
in mouse model of Huntington's disease. J. Neurosci., 27, 4424-4434. 
 135.  Brito,V., Giralt,A., Enriquez-Barreto,L., Puigdellivol,M., Suelves,N., Zamora-
Moratalla,A., Ballesteros,J.J., Martin,E.D., Dominguez-Iturza,N., Morales,M., et 
al. (2014) Neurotrophin receptor p75(NTR) mediates Huntington's disease-
associated synaptic and memory dysfunction. J. Clin. Invest, 124, 4411-4428. 
 136.  Puigdellivol,M., Cherubini,M., Brito,V., Giralt,A., Suelves,N., Ballesteros,J., 
Zamora-Moratalla,A., Martin,E.D., Eipper,B.A., Alberch,J., Gines,S. (2015) A role 
for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease. 
Hum. Mol. Genet. 24, 7265-7285. 
 137.  Deng,Y.P., Wong,T., Wan,J.Y., Reiner,A. (2014) Differential loss of 
thalamostriatal and corticostriatal input to striatal projection neuron types 
prior to overt motor symptoms in the Q140 knock-in mouse model of 
Huntington's disease. Front Syst. Neurosci., 8, 198. 
 138.  Lerner,R.P., Trejo Martinez,L.C., Zhu,C., Chesselet,M.F., Hickey,M.A. (2012) 
Striatal atrophy and dendritic alterations in a knock-in mouse model of 
Huntington's disease. Brain Res. Bull., 87, 571-578. 
 139.  Giralt,A., Saavedra,A., Carreton,O., Xifro,X., Alberch,J., Perez-Navarro,E. (2011) 
Increased PKA signaling disrupts recognition memory and spatial memory: role 
in Huntington's disease. Hum. Mol. Genet., 20, 4232-4247. 
 140.  Carter,R.J., Lione,L.A., Humby,T., Mangiarini,L., Mahal,A., Bates,G.P., 
Dunnett,S.B., Morton,A.J. (1999) Characterization of progressive motor deficits 
in mice transgenic for the human Huntington's disease mutation. J. Neurosci., 
19, 3248-3257. 
 141.  Giralt,A., Carreton,O., Lao-Peregrin,C., Martin,E.D., Alberch,J. (2011) 
Conditional BDNF release under pathological conditions improves Huntington's 
disease pathology by delaying neuronal dysfunction. Mol. Neurodegener., 6, 71. 
 142.  Stack,E.C., Kubilus,J.K., Smith,K., Cormier,K., Del Signore,S.J., Guelin,E., Ryu,H., 
Hersch,S.M., Ferrante,R.J. (2005) Chronology of behavioral symptoms and 
neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. 
Comp Neurol., 490, 354-370. 
Page 34 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
35 
 
 143.  McBride,J.L., Ramaswamy,S., Gasmi,M., Bartus,R.T., Herzog,C.D., Brandon,E.P., 
Zhou,L., Pitzer,M.R., Berry-Kravis,E.M., Kordower,J.H. (2006) Viral delivery of 
glial cell line-derived neurotrophic factor improves behavior and protects 
striatal neurons in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. 
U. S. A, 103, 9345-9350. 
 144.  Ramaswamy,S., McBride,J.L., Kordower,J.H. (2007) Animal models of 
Huntington's disease. ILAR. J., 48, 356-373. 
 145.  Diaz-Hernandez,M., Torres-Peraza,J., Salvatori-Abarca,A., Moran,M.A., Gomez-
Ramos,P., Alberch,J., Lucas,J.J. (2005) Full motor recovery despite striatal 
neuron loss and formation of irreversible amyloid-like inclusions in a 
conditional mouse model of Huntington's disease. J. Neurosci., 25, 9773-9781. 
 146.  van Raamsdonk,J.M., Pearson,J., Rogers,D.A., Bissada,N., Vogl,A.W., 
Hayden,M.R., Leavitt,B.R. (2005) Loss of wild-type huntingtin influences motor 
dysfunction and survival in the YAC128 mouse model of Huntington disease. 
Hum. Mol. Genet., 14, 1379-1392. 
 147.  van Raamsdonk,J.M., Pearson,J., Slow,E.J., Hossain,S.M., Leavitt,B.R., 
Hayden,M.R. (2005) Cognitive dysfunction precedes neuropathology and motor 
abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci., 
25, 4169-4180. 
 148.  Brooks,S., Higgs,G., Jones,L., Dunnett,S.B. (2012) Longitudinal analysis of the 
behavioural phenotype in HdhQ92 Huntington's disease knock-in mice. Brain 
Res. Bull., 88, 148-155. 
 149.  Trueman,R.C., Brooks,S.P., Jones,L., Dunnett,S.B. (2007) The operant serial 
implicit learning task reveals early onset motor learning deficits in the Hdh 
knock-in mouse model of Huntington's disease. Eur. J. Neurosci., 25, 551-558. 
 150.  Giralt,A., Puigdellivol,M., Carreton,O., Paoletti,P., Valero,J., Parra-Damas,A., 
Saura,C.A., Alberch,J., Gines,S. (2012) Long-term memory deficits in 
Huntington's disease are associated with reduced CBP histone acetylase 
activity. Hum. Mol. Genet., 21, 1203-1216. 
 151.  Yhnell,E., Lelos,M.J., Dunnett,S.B., Brooks,S.P. (2016) Cognitive training 
modifies disease symptoms in a mouse model of Huntington's disease. Exp. 
Neurol., 282, 19-26. 
 152.  Yhnell,E., Dunnett,S.B., Brooks,S.P. (2016) A longitudinal motor characterisation 
of the hdhq111 mouse model of Huntington's disease. J. Huntingtons. Dis.. May 
31. doi: 10.3233/JHD-160191. (Epub ahead of print).  
 153.  Hickey,M.A., Kosmalska,A., Enayati,J., Cohen,R., Zeitlin,S., Levine,M.S., 
Chesselet,M.F. (2008) Extensive early motor and non-motor behavioral deficits 
are followed by striatal neuronal loss in knock-in Huntington's disease mice. 
Neuroscience, 157, 280-295. 
Page 35 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
36 
 
 154.  Brooks,S., Higgs,G., Jones,L., Dunnett,S.B. (2012) Longitudinal analysis of the 
behavioural phenotype in Hdh(CAG)150 Huntington's disease knock-in mice. 
Brain Res. Bull., 88, 182-188. 
 155.  Marder,K., Zhao,H., Myers,R.H., Cudkowicz,M., Kayson,E., Kieburtz,K., Orme,C., 
Paulsen,J., Penney,J.B., Jr., Siemers,E., Shoulson,I. (2000) Rate of functional 
decline in Huntington's disease. Huntington Study Group. Neurology, 54, 452-
458. 
 156.  Orth,M., Schippling,S., Schneider,S.A., Bhatia,K.P., Talelli,P., Tabrizi,S.J., 
Rothwell,J.C. (2010) Abnormal motor cortex plasticity in premanifest and very 
early manifest Huntington disease. J. Neurol. Neurosurg. Psychiatry, 81, 267-
270. 
 157.  Schippling,S., Schneider,S.A., Bhatia,K.P., Munchau,A., Rothwell,J.C., Tabrizi,S.J., 
Orth,M. (2009) Abnormal motor cortex excitability in preclinical and very early 
Huntington's disease. Biol. Psychiatry, 65, 959-965. 
 158.  Verny,C., Allain,P., Prudean,A., Malinge,M.C., Gohier,B., Scherer,C., Bonneau,D., 
Dubas,F., Le,G.D. (2007) Cognitive changes in asymptomatic carriers of the 
Huntington disease mutation gene. Eur. J. Neurol., 14, 1344-1350. 
 159.  Shirasaki,D.I., Greiner,E.R., Al-Ramahi,I., Gray,M., Boontheung,P., 
Geschwind,D.H., Botas,J., Coppola,G., Horvath,S., Loo,J.A., Yang,X.W. (2012) 
Network organization of the huntingtin proteomic interactome in mammalian 
brain. Neuron, 75, 41-57. 
 160.  Parker,J.A., Metzler,M., Georgiou,J., Mage,M., Roder,J.C., Rose,A.M., 
Hayden,M.R., Neri,C. (2007) Huntingtin-interacting protein 1 influences worm 
and mouse presynaptic function and protects Caenorhabditis elegans neurons 
against mutant polyglutamine toxicity. J. Neurosci., 27, 11056-11064. 
 161.  Smith,R., Brundin,P., Li,J.Y. (2005) Synaptic dysfunction in Huntington's disease: 
a new perspective. Cell Mol. Life Sci., 62, 1901-1912. 
 162.  Suopanki,J., Gotz,C., Lutsch,G., Schiller,J., Harjes,P., Herrmann,A., Wanker,E.E. 
(2006) Interaction of huntingtin fragments with brain membranes--clues to 
early dysfunction in Huntington's disease. J. Neurochem., 96, 870-884. 
 163.  Labbadia,J., Morimoto,R.I. (2013) Huntington's disease: underlying molecular 
mechanisms and emerging concepts. Trends Biochem. Sci., 38, 378-385. 
 164.  Zuccato,C., Valenza,M., Cattaneo,E. (2010) Molecular mechanisms and 
potential therapeutical targets in Huntington's disease. Physiol Rev., 90, 905-
981. 
 165.  Zuccato,C., Liber,D., Ramos,C., Tarditi,A., Rigamonti,D., Tartari,M., Valenza,M., 
Cattaneo,E. (2005) Progressive loss of BDNF in a mouse model of Huntington's 
disease and rescue by BDNF delivery. Pharmacol. Res., 52, 133-139. 
Page 36 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
37 
 
 166.  Shepherd,G.M., Erulkar,S.D. (1997) Centenary of the synapse: from Sherrington 
to the molecular biology of the synapse and beyond. Trends Neurosci., 20, 385-
392. 
 167.  van der Zee,E.A. (2014) Synapses, spines and kinases in mammalian learning 
and memory, and the impact of aging. Neurosci. Biobehav. Rev. 50, 77–85. 
 168.  von Bohlen Und,H.O. (2009) Structure and function of dendritic spines within 
the hippocampus. Ann. Anat., 191, 518-531. 
 169.  Graveland,G.A., Williams,R.S., DiFiglia,M. (1985) Evidence for degenerative and 
regenerative changes in neostriatal spiny neurons in Huntington's disease. 
Science, 227, 770-773. 
 170.  Sotrel,A., Williams,R.S., Kaufmann,W.E., Myers,R.H. (1993) Evidence for 
neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of 
Huntington's disease: a quantitative Golgi study. Neurology, 43, 2088-2096. 
 171.  Penzes,P., Jones,K.A. (2008) Dendritic spine dynamics--a key role for kalirin-7. 
Trends Neurosci., 31, 419-427. 
 172.  Ma,X.M., Huang,J., Wang,Y., Eipper,B.A., Mains,R.E. (2003) Kalirin, a 
multifunctional Rho guanine nucleotide exchange factor, is necessary for 
maintenance of hippocampal pyramidal neuron dendrites and dendritic spines. 
J. Neurosci., 23, 10593-10603. 
 173.  Ma,X.M., Kiraly,D.D., Gaier,E.D., Wang,Y., Kim,E.J., Levine,E.S., Eipper,B.A., 
Mains,R.E. (2008) Kalirin-7 is required for synaptic structure and function. J. 
Neurosci., 28, 12368-12382. 
 174.  Penzes,P., Johnson,R.C., Sattler,R., Zhang,X., Huganir,R.L., Kambampati,V., 
Mains,R.E., Eipper,B.A. (2001) The neuronal Rho-GEF Kalirin-7 interacts with 
PDZ domain-containing proteins and regulates dendritic morphogenesis. 
Neuron, 29, 229-242. 
 175.  Penzes,P., Johnson,R.C., Kambampati,V., Mains,R.E., Eipper,B.A. (2001) Distinct 
roles for the two Rho GDP/GTP exchange factor domains of kalirin in regulation 
of neurite growth and neuronal morphology. J. Neurosci., 21, 8426-8434. 
 176.  Cahill,M.E., Xie,Z., Day,M., Photowala,H., Barbolina,M.V., Miller,C.A., Weiss,C., 
Radulovic,J., Sweatt,J.D., Disterhoft,J.F., et al. (2009) Kalirin regulates cortical 
spine morphogenesis and disease-related behavioral phenotypes. Proc. Natl. 
Acad. Sci. U. S. A, 106, 13058-13063. 
 177.  Xie,Z., Cahill,M.E., Radulovic,J., Wang,J., Campbell,S.L., Miller,C.A., Sweatt,J.D., 
Penzes,P. (2011) Hippocampal phenotypes in kalirin-deficient mice. Mol. Cell 
Neurosci., 46, 45-54. 
Page 37 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
38 
 
 178.  Colomer,V., Engelender,S., Sharp,A.H., Duan,K., Cooper,J.K., Lanahan,A., 
Lyford,G., Worley,P., Ross,C.A. (1997) Huntingtin-associated protein 1 (HAP1) 
binds to a Trio-like polypeptide, with a rac1 guanine nucleotide exchange factor 
domain. Hum. Mol. Genet., 6, 1519-1525. 
 179.  Sepers,M.D., Raymond,L.A. (2014) Mechanisms of synaptic dysfunction and 
excitotoxicity in Huntington's disease. Drug Discov. Today, 19, 990-996. 
 180.  Levine,M.S., Klapstein,G.J., Koppel,A., Gruen,E., Cepeda,C., Vargas,M.E., 
Jokel,E.S., Carpenter,E.M., Zanjani,H., Hurst,R.S., et al. (1999) Enhanced 
sensitivity to N-methyl-D-aspartate receptor activation in transgenic and 
knockin mouse models of Huntington's disease. J. Neurosci. Res., 58, 515-532. 
 181.  Milnerwood,A.J., Gladding,C.M., Pouladi,M.A., Kaufman,A.M., Hines,R.M., 
Boyd,J.D., Ko,R.W., Vasuta,O.C., Graham,R.K., Hayden,M.R., et al. (2010) Early 
increase in extrasynaptic NMDA receptor signaling and expression contributes 
to phenotype onset in Huntington's disease mice. Neuron, 65, 178-190. 
 182.  Perez-Otano,I., Lujan,R., Tavalin,S.J., Plomann,M., Modregger,J., Liu,X.B., 
Jones,E.G., Heinemann,S.F., Lo,D.C., Ehlers,M.D. (2006) Endocytosis and 
synaptic removal of NR3A-containing NMDA receptors by PACSIN1/syndapin1. 
Nat. Neurosci., 9, 611-621. 
 183.  Kehoe,L.A., Bellone,C., De,R.M., Zandueta,A., Dey,P.N., Perez-Otano,I., 
Muller,D. (2014) GluN3A promotes dendritic spine pruning and destabilization 
during postnatal development. J. Neurosci., 34, 9213-9221. 
 184.  Roberts,A.C., Diez-Garcia,J., Rodriguiz,R.M., Lopez,I.P., Lujan,R., Martinez-
Turrillas,R., Pico,E., Henson,M.A., Bernardo,D.R., Jarrett,T.M., et al. (2009) 
Downregulation of NR3A-containing NMDARs is required for synapse 
maturation and memory consolidation. Neuron, 63, 342-356. 
 185.  Wong,H.K., Liu,X.B., Matos,M.F., Chan,S.F., Perez-Otano,I., Boysen,M., Cui,J., 
Nakanishi,N., Trimmer,J.S., Jones,E.G., et al. (2002) Temporal and regional 
expression of NMDA receptor subunit NR3A in the mammalian brain. J. Comp 
Neurol., 450, 303-317. 
 186.  Bezprozvanny,I. (2009) Calcium signaling and neurodegenerative diseases. 
Trends Mol. Med., 15, 89-100. 
 187.  Bezprozvanny,I. (2011) Role of inositol 1,4,5-trisphosphate receptors in 
pathogenesis of Huntington's disease and spinocerebellar ataxias. Neurochem. 
Res., 36, 1186-1197. 
 188.  Miller,B.R., Bezprozvanny,I. (2010) Corticostriatal circuit dysfunction in 
Huntington's disease: intersection of glutamate, dopamine and calcium. Future. 
Neurol., 5, 735-756. 
Page 38 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
39 
 
 189.  Tang,T.S., Tu,H., Chan,E.Y., Maximov,A., Wang,Z., Wellington,C.L., Hayden,M.R., 
Bezprozvanny,I. (2003) Huntingtin and huntingtin-associated protein 1 
influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate 
receptor type 1. Neuron, 39, 227-239. 
 190.  Tang,T.S., Slow,E., Lupu,V., Stavrovskaya,I.G., Sugimori,M., Llinas,R., Kristal,B.S., 
Hayden,M.R., Bezprozvanny,I. (2005) Disturbed Ca2+ signaling and apoptosis of 
medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A, 
102, 2602-2607. 
 191.  Putney,J.W., Jr. (2003) Capacitative calcium entry in the nervous system. Cell 
Calcium, 34, 339-344. 
 192.  Popugaeva,E., Pchitskaya,E., Speshilova,A., Alexandrov,S., Zhang,H., Vlasova,O., 
Bezprozvanny,I. (2015) STIM2 protects hippocampal mushroom spines from 
amyloid synaptotoxicity. Mol. Neurodegener., 10, 37. 
 193.  Sun,S., Zhang,H., Liu,J., Popugaeva,E., Xu,N.J., Feske,S., White,C.L., III, 
Bezprozvanny,I. (2014) Reduced synaptic STIM2 expression and impaired store-
operated calcium entry cause destabilization of mature spines in mutant 
presenilin mice. Neuron, 82, 79-93. 
 194.  Zhang,H., Wu,L., Pchitskaya,E., Zakharova,O., Saito,T., Saido,T., Bezprozvanny,I. 
(2015) Neuronal store-operated calcium entry and mushroom spine loss in 
amyloid precursor protein knock-in mouse model of Alzheimer's disease. J. 
Neurosci., 35, 13275-13286. 
 195.  Wu,J., Shih,H.P., Vigont,V., Hrdlicka,L., Diggins,L., Singh,C., Mahoney,M., 
Chesworth,R., Shapiro,G., Zimina,O., et al. (2011) Neuronal store-operated 
calcium entry pathway as a novel therapeutic target for Huntington's disease 
treatment. Chem. Biol., 18, 777-793. 
 196.  Ferrer,I., Goutan,E., Marin,C., Rey,M.J., Ribalta,T. (2000) Brain-derived 
neurotrophic factor in Huntington disease. Brain Res., 866, 257-261. 
 197.  Gines,S., Seong,I.S., Fossale,E., Ivanova,E., Trettel,F., Gusella,J.F., Wheeler,V.C., 
Persichetti,F., MacDonald,M.E. (2003) Specific progressive cAMP reduction 
implicates energy deficit in presymptomatic Huntington's disease knock-in 
mice. Hum. Mol. Genet., 12, 497-508. 
 198.  Zuccato,C., Ciammola,A., Rigamonti,D., Leavitt,B.R., Goffredo,D., Conti,L., 
MacDonald,M.E., Friedlander,R.M., Silani,V., Hayden,M.R., et al. (2001) Loss of 
huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 
293, 493-498. 
 199.  Zuccato,C., Cattaneo,E. (2007) Role of brain-derived neurotrophic factor in 
Huntington's disease. Prog. Neurobiol., 81, 294-330. 
Page 39 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
40 
 
 200.  Zuccato,C., Cattaneo,E. (2009) Brain-derived neurotrophic factor in 
neurodegenerative diseases. Nat. Rev. Neurol., 5, 311-322. 
 201.  Plotkin,J.L., Day,M., Peterson,J.D., Xie,Z., Kress,G.J., Rafalovich,I., Kondapalli,J., 
Gertler,T.S., Flajolet,M., Greengard,P., et al. (2014) Impaired TrkB receptor 
signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron, 
83, 178-188. 
 202.  Numakawa,T., Yokomaku,D., Richards,M., Hori,H., Adachi,N., Kunugi,H. (2010) 
Functional interactions between steroid hormones and neurotrophin BDNF. 
World J. Biol. Chem., 1, 133-143. 
 203.  Skaper,S.D. (2012) The neurotrophin family of neurotrophic factors: an 
overview. Methods Mol. Biol., 846, 1-12. 
 204.  Bibel,M., Hoppe,E., Barde,Y.A. (1999) Biochemical and functional interactions 
between the neurotrophin receptors trk and p75NTR. EMBO J., 18, 616-622. 
 205.  Ceni,C., Kommaddi,R.P., Thomas,R., Vereker,E., Liu,X., McPherson,P.S., 
Ritter,B., Barker,P.A. (2010) The p75NTR intracellular domain generated by 
neurotrophin-induced receptor cleavage potentiates Trk signaling. J. Cell Sci., 
123, 2299-2307. 
 206.  MacPhee,I.J., Barker,P.A. (1997) Brain-derived neurotrophic factor binding to 
the p75 neurotrophin receptor reduces TrkA signaling while increasing serine 
phosphorylation in the TrkA intracellular domain. J. Biol. Chem., 272, 23547-
23551. 
 207.  Song,W., Volosin,M., Cragnolini,A.B., Hempstead,B.L., Friedman,W.J. (2010) 
ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in 
brain neurons. J. Neurosci., 30, 15608-15615. 
 208.  Coulson,E.J., May,L.M., Osborne,S.L., Reid,K., Underwood,C.K., Meunier,F.A., 
Bartlett,P.F., Sah,P. (2008) p75 neurotrophin receptor mediates neuronal cell 
death by activating GIRK channels through phosphatidylinositol 4,5-
bisphosphate. J. Neurosci., 28, 315-324. 
 209.  Friedman,W.J. (2000) Neurotrophins induce death of hippocampal neurons via 
the p75 receptor. J. Neurosci., 20, 6340-6346. 
 210.  Troy,C.M., Friedman,J.E., Friedman,W.J. (2002) Mechanisms of p75-mediated 
death of hippocampal neurons. Role of caspases. J. Biol. Chem., 277, 34295-
34302. 
 211.  Poo,M.M. (2001) Neurotrophins as synaptic modulators. Nat. Rev. Neurosci., 2, 
24-32. 
 212.  Rosch,H., Schweigreiter,R., Bonhoeffer,T., Barde,Y.A., Korte,M. (2005) The 
neurotrophin receptor p75NTR modulates long-term depression and regulates 
Page 40 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
41 
 
the expression of AMPA receptor subunits in the hippocampus. Proc. Natl. 
Acad. Sci. U. S. A, 102, 7362-7367. 
 213.  Woo,N.H., Teng,H.K., Siao,C.J., Chiaruttini,C., Pang,P.T., Milner,T.A., 
Hempstead,B.L., Lu,B. (2005) Activation of p75NTR by proBDNF facilitates 
hippocampal long-term depression. Nat. Neurosci., 8, 1069-1077. 
 214.  Lu,B., Pang,P.T., Woo,N.H. (2005) The yin and yang of neurotrophin action. Nat. 
Rev. Neurosci., 6, 603-614. 
 215.  Baquet,Z.C., Gorski,J.A., Jones,K.R. (2004) Early striatal dendrite deficits 
followed by neuron loss with advanced age in the absence of anterograde 
cortical brain-derived neurotrophic factor. J. Neurosci., 24, 4250-4258. 
 216.  Gorski,J.A., Zeiler,S.R., Tamowski,S., Jones,K.R. (2003) Brain-derived 
neurotrophic factor is required for the maintenance of cortical dendrites. J. 
Neurosci., 23, 6856-6865. 
 217.  Yamashita,T., Tucker,K.L., Barde,Y.A. (1999) Neurotrophin binding to the p75 
receptor modulates Rho activity and axonal outgrowth. Neuron, 24, 585-593. 
 218.  Gines,S., Bosch,M., Marco,S., Gavalda,N., Diaz-Hernandez,M., Lucas,J.J., 
Canals,J.M., Alberch,J. (2006) Reduced expression of the TrkB receptor in 
Huntington's disease mouse models and in human brain. Eur. J. Neurosci., 23, 
649-658. 
 219.  Gines,S., Paoletti,P., Alberch,J. (2010) Impaired TrkB-mediated ERK1/2 
activation in huntington disease knock-in striatal cells involves reduced 
p52/p46 Shc expression. J. Biol. Chem., 285, 21537-21548. 
 220.  Zuccato,C., Marullo,M., Conforti,P., MacDonald,M.E., Tartari,M., Cattaneo,E. 
(2008) Systematic assessment of BDNF and its receptor levels in human cortices 
affected by Huntington's disease. Brain Pathol., 18, 225-238. 
 221.  Brito,V., Puigdellivol,M., Giralt,A., del,T.D., Alberch,J., Gines,S. (2013) Imbalance 
of p75(NTR)/TrkB protein expression in Huntington's disease: implication for 
neuroprotective therapies. Cell Death. Dis., 4, e595. 
 222.  Zagrebelsky,M., Holz,A., Dechant,G., Barde,Y.A., Bonhoeffer,T., Korte,M. (2005) 
The p75 neurotrophin receptor negatively modulates dendrite complexity and 
spine density in hippocampal neurons. J. Neurosci., 25, 9989-9999. 
 223.  Barrett,G.L., Reid,C.A., Tsafoulis,C., Zhu,W., Williams,D.A., Paolini,A.G., Trieu,J., 
Murphy,M. (2010) Enhanced spatial memory and hippocampal long-term 
potentiation in p75 neurotrophin receptor knockout mice. Hippocampus, 20, 
145-152. 
Page 41 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
42 
 
 224.  Greferath,U., Bennie,A., Kourakis,A., Bartlett,P.F., Murphy,M., Barrett,G.L. 
(2000) Enlarged cholinergic forebrain neurons and improved spatial learning in 
p75 knockout mice. Eur. J. Neurosci., 12, 885-893. 
 225.  Brooks,S., Higgs,G., Janghra,N., Jones,L., Dunnett,S.B. (2012) Longitudinal 
analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's 
disease transgenic mice. Brain Res. Bull., 88, 113-120. 
 226.  Brooks,S.P., Betteridge,H., Trueman,R.C., Jones,L., Dunnett,S.B. (2006) Selective 
extra-dimensional set shifting deficit in a knock-in mouse model of 
Huntington's disease. Brain Res. Bull., 69, 452-457. 
 227.  Brooks,S.P., Janghra,N., Higgs,G.V., Bayram-Weston,Z., Heuer,A., Jones,L., 
Dunnett,S.B. (2012) Selective cognitive impairment in the YAC128 Huntington's 
disease mouse. Brain Res. Bull., 88, 121-129. 
 228.  Brooks,S.P., Dunnett,S.B. (2013) Cognitive deficits in animal models of basal 
ganglia disorders. Brain Res. Bull., 92, 29-40. 
 229.  Mazarakis,N.K., Cybulska-Klosowicz,A., Grote,H., Pang,T., van,D.A., Kossut,M., 
Blakemore,C., Hannan,A.J. (2005) Deficits in experience-dependent cortical 
plasticity and sensory-discrimination learning in presymptomatic Huntington's 
disease mice. J. Neurosci., 25, 3059-3066. 
 230.  Giralt,A., Saavedra,A., Alberch,J., Perez-Navarro,E. (2012) Cognitive dysfunction 
in Huntington's disease: humans, mouse models and molecular mechanisms. J. 
Huntingtons. Dis., 1, 155-173. 
 231.  Papp,K.V., Kaplan,R.F., Snyder,P.J. (2011) Biological markers of cognition in 
prodromal Huntington's disease: a review. Brain Cogn, 77, 280-291. 
 232.  Cepeda,C., Cummings,D.M., Hickey,M.A., Kleiman-Weiner,M., Chen,J.Y., 
Watson,J.B., Levine,M.S. (2010) Rescuing the corticostriatal synaptic 
disconnection in the R6/2 mouse model of Huntington's Disease: exercise, 
adenosine receptors and ampakines. PLoS. Curr., 2, RRN1182. 
 233.  Li,W., Silva,H.B., Real,J., Wang,Y.M., Rial,D., Li,P., Payen,M.P., Zhou,Y., 
Muller,C.E., Tome,A.R., et al. (2015) Inactivation of adenosine A2A receptors 
reverses working memory deficits at early stages of Huntington's disease 
models. Neurobiol. Dis., 79, 70-80. 
 234.  Kennedy,M.B., Beale,H.C., Carlisle,H.J., Washburn,L.R. (2005) Integration of 
biochemical signalling in spines. Nat. Rev. Neurosci., 6, 423-434. 
 235.  Mansuy,I.M., Shenolikar,S. (2006) Protein serine/threonine phosphatases in 
neuronal plasticity and disorders of learning and memory. Trends Neurosci., 29, 
679-686. 
Page 42 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
43 
 
 236.  Mayford,M. (2007) Protein kinase signaling in synaptic plasticity and memory. 
Curr. Opin. Neurobiol., 17, 313-317. 
 237.  Ehrnhoefer,D.E., Sutton,L., Hayden,M.R. (2011) Small changes, big impact: 
posttranslational modifications and function of huntingtin in Huntington 
disease. Neuroscientist., 17, 475-492. 
 238.  Fan,M.M., Zhang,H., Hayden,M.R., Pelech,S.L., Raymond,L.A. (2008) Protective 
up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA 
receptors. J. Neurochem., 104, 790-805. 
 239.  Metzler,M., Gan,L., Mazarei,G., Graham,R.K., Liu,L., Bissada,N., Lu,G., 
Leavitt,B.R., Hayden,M.R. (2010) Phosphorylation of huntingtin at Ser421 in 
YAC128 neurons is associated with protection of YAC128 neurons from NMDA-
mediated excitotoxicity and is modulated by PP1 and PP2A. J. Neurosci., 30, 
14318-14329. 
 240.  Pineda,J.R., Pardo,R., Zala,D., Yu,H., Humbert,S., Saudou,F. (2009) Genetic and 
pharmacological inhibition of calcineurin corrects the BDNF transport defect in 
Huntington's disease. Mol. Brain, 2, 33. 
 241.  Runne,H., Regulier,E., Kuhn,A., Zala,D., Gokce,O., Perrin,V., Sick,B., 
Aebischer,P., Deglon,N., Luthi-Carter,R. (2008) Dysregulation of gene 
expression in primary neuron models of Huntington's disease shows that 
polyglutamine-related effects on the striatal transcriptome may not be 
dependent on brain circuitry. J. Neurosci., 28, 9723-9731. 
 242.  Saavedra,A., Garcia-Martinez,J.M., Xifro,X., Giralt,A., Torres-Peraza,J.F., 
Canals,J.M., Diaz-Hernandez,M., Lucas,J.J., Alberch,J., Perez-Navarro,E. (2010) 
PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain 
the activation of the PI3K/Akt pro-survival pathway in Huntington's disease 
striatum. Cell Death. Differ., 17, 324-335. 
 243.  Saavedra,A., Giralt,A., Rue,L., Xifro,X., Xu,J., Ortega,Z., Lucas,J.J., Lombroso,P.J., 
Alberch,J., Perez-Navarro,E. (2011) Striatal-enriched protein tyrosine 
phosphatase expression and activity in Huntington's disease: a STEP in the 
resistance to excitotoxicity. J. Neurosci., 31, 8150-8162. 
 244.  Wu,Z.L., O'Kane,T.M., Scott,R.W., Savage,M.J., Bozyczko-Coyne,D. (2002) 
Protein tyrosine phosphatases are up-regulated and participate in cell death 
induced by polyglutamine expansion. J. Biol. Chem., 277, 44208-44213. 
 245.  Xifro,X., Garcia-Martinez,J.M., del,T.D., Alberch,J., Perez-Navarro,E. (2008) 
Calcineurin is involved in the early activation of NMDA-mediated cell death in 
mutant huntingtin knock-in striatal cells. J. Neurochem., 105, 1596-1612. 
 246.  Xifro,X., Giralt,A., Saavedra,A., Garcia-Martinez,J.M., Diaz-Hernandez,M., 
Lucas,J.J., Alberch,J., Perez-Navarro,E. (2009) Reduced calcineurin protein levels 
Page 43 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
44 
 
and activity in exon-1 mouse models of Huntington's disease: role in 
excitotoxicity. Neurobiol. Dis., 36, 461-469. 
 247.  Apostol,B.L., Illes,K., Pallos,J., Bodai,L., Wu,J., Strand,A., Schweitzer,E.S., 
Olson,J.M., Kazantsev,A., Marsh,J.L., Thompson,L.M. (2006) Mutant huntingtin 
alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects 
against mutant huntingtin-associated toxicity. Hum. Mol. Genet., 15, 273-285. 
 248.  Fan,J., Gladding,C.M., Wang,L., Zhang,L.Y., Kaufman,A.M., Milnerwood,A.J., 
Raymond,L.A. (2012) P38 MAPK is involved in enhanced NMDA receptor-
dependent excitotoxicity in YAC transgenic mouse model of Huntington 
disease. Neurobiol. Dis., 45, 999-1009. 
 249.  Gines,S., Ivanova,E., Seong,I.S., Saura,C.A., MacDonald,M.E. (2003) Enhanced 
Akt signaling is an early pro-survival response that reflects N-methyl-D-
aspartate receptor activation in Huntington's disease knock-in striatal cells. J. 
Biol. Chem., 278, 50514-50522. 
 250.  Paoletti,P., Vila,I., Rife,M., Lizcano,J.M., Alberch,J., Gines,S. (2008) 
Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease 
neurodegeneration: the role of p25/cyclin-dependent kinase 5. J. Neurosci., 28, 
10090-10101. 
 251.  Roze,E., Betuing,S., Deyts,C., Marcon,E., Brami-Cherrier,K., Pages,C., 
Humbert,S., Merienne,K., Caboche,J. (2008) Mitogen- and stress-activated 
protein kinase-1 deficiency is involved in expanded-huntingtin-induced 
transcriptional dysregulation and striatal death. FASEB J., 22, 1083-1093. 
 252.  Rue,L., Alcala-Vida,R., Lopez-Soop,G., Creus-Muncunill,J., Alberch,J., Perez-
Navarro,E. (2014) Early down-regulation of PKCdelta as a pro-survival 
mechanism in Huntington's disease. Neuromolecular. Med., 16, 25-37. 
 253.  Xifro,X., Anglada-Huguet,M., Rue,L., Saavedra,A., Perez-Navarro,E., Alberch,J. 
(2011) Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against 
mutant huntingtin toxicity. Mol. Neurodegener., 6, 74. 
 254.  Bowles,K.R., Jones,L. (2014) Kinase signalling in Huntington's disease. J. 
Huntingtons. Dis., 3, 89-123. 
 255.  Nguyen,P.V., Woo,N.H. (2003) Regulation of hippocampal synaptic plasticity by 
cyclic AMP-dependent protein kinases. Prog. Neurobiol., 71, 401-437. 
 256.  Abel,T., Nguyen,P.V. (2008) Regulation of hippocampus-dependent memory by 
cyclic AMP-dependent protein kinase. Prog. Brain Res., 169, 97-115. 
 257.  Kandel,E.R. (2012) The molecular biology of memory: cAMP, PKA, CRE, CREB-1, 
CREB-2, and CPEB. Mol. Brain, 5, 14. 
Page 44 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
45 
 
 258.  Bourtchouladze,R., Patterson,S.L., Kelly,M.P., Kreibich,A., Kandel,E.R., Abel,T. 
(2006) Chronically increased Gsalpha signaling disrupts associative and spatial 
learning. Learn. Mem., 13, 745-752. 
 259.  Dubnau,J., Tully,T. (1998) Gene discovery in Drosophila: new insights for 
learning and memory. Annu. Rev. Neurosci., 21, 407-444. 
 260.  Kelly,M.P., Cheung,Y.F., Favilla,C., Siegel,S.J., Kanes,S.J., Houslay,M.D., Abel,T. 
(2008) Constitutive activation of the G-protein subunit Galphas within forebrain 
neurons causes PKA-dependent alterations in fear conditioning and cortical Arc 
mRNA expression. Learn. Mem., 15, 75-83. 
 261.  Morton,A.J. (2013) Circadian and sleep disorder in Huntington's disease. Exp. 
Neurol., 243, 34-44. 
 262.  Gonzales,E.D., Tanenhaus,A.K., Zhang,J., Chaffee,R.P., Yin,J.C. (2016) Early-
onset sleep defects in Drosophila models of Huntington's disease reflect 
alterations of PKA/CREB signaling. Hum. Mol. Genet., 25, 837-852. 
 263.  Kleppisch,T., Feil,R. (2009) cGMP signalling in the mammalian brain: role in 
synaptic plasticity and behaviour. Handb. Exp. Pharmacol.,  191, 549-579. 
 264.  Norris,P.J., Waldvogel,H.J., Faull,R.L., Love,D.R., Emson,P.C. (1996) Decreased 
neuronal nitric oxide synthase messenger RNA and somatostatin messenger 
RNA in the striatum of Huntington's disease. Neuroscience, 72, 1037-1047. 
 265.  Deckel,A.W., Gordinier,A., Nuttal,D., Tang,V., Kuwada,C., Freitas,R., Gary,K.A. 
(2001) Reduced activity and protein expression of NOS in R6/2 HD transgenic 
mice: effects of L-NAME on symptom progression. Brain Res., 919, 70-81. 
 266.  Deckel,A.W., Elder,R., Fuhrer,G. (2002) Biphasic developmental changes in 
Ca2+/calmodulin-dependent proteins in R6/2 Huntington's disease mice. 
Neuroreport, 13, 707-711. 
 267.  Deckel,A.W., Tang,V., Nuttal,D., Gary,K., Elder,R. (2002) Altered neuronal nitric 
oxide synthase expression contributes to disease progression in Huntington's 
disease transgenic mice. Brain Res., 939, 76-86. 
 268.  Jarabek,B.R., Yasuda,R.P., Wolfe,B.B. (2004) Regulation of proteins affecting 
NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain, 
127, 505-516. 
 269.  Perez-Severiano,F., Escalante,B., Vergara,P., Rios,C., Segovia,J. (2002) Age-
dependent changes in nitric oxide synthase activity and protein expression in 
striata of mice transgenic for the Huntington's disease mutation. Brain Res., 
951, 36-42. 
 270.  Boolell,M., Allen,M.J., Ballard,S.A., Gepi-Attee,S., Muirhead,G.J., Naylor,A.M., 
Osterloh,I.H., Gingell,C. (1996) Sildenafil: an orally active type 5 cyclic GMP-
Page 45 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
46 
 
specific phosphodiesterase inhibitor for the treatment of penile erectile 
dysfunction. Int. J. Impot. Res., 8, 47-52. 
 271.  Saavedra,A., Giralt,A., Arumi,H., Alberch,J., Perez-Navarro,E. (2013) Regulation 
of hippocampal cGMP levels as a candidate to treat cognitive deficits in 
Huntington's disease. PLoS. One., 8, e73664. 
 272.  Thakur,T., Sharma,S., Kumar,K., Deshmukh,R., Sharma,P.L. (2013) 
Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid 
induced behavioral and biochemical toxicities in rats. Eur. J. Pharmacol., 714, 
515-521. 
 273.  Desplats,P.A., Kass,K.E., Gilmartin,T., Stanwood,G.D., Woodward,E.L., 
Head,S.R., Sutcliffe,J.G., Thomas,E.A. (2006) Selective deficits in the expression 
of striatal-enriched mRNAs in Huntington's disease. J. Neurochem., 96, 743-757. 
 274.  Hodges,A., Strand,A.D., Aragaki,A.K., Kuhn,A., Sengstag,T., Hughes,G., 
Elliston,L.A., Hartog,C., Goldstein,D.R., Thu,D., et al. (2006) Regional and 
cellular gene expression changes in human Huntington's disease brain. Hum. 
Mol. Genet., 15, 965-977. 
 275.  Lee,S.T., Chu,K., Im,W.S., Yoon,H.J., Im,J.Y., Park,J.E., Park,K.H., Jung,K.H., 
Lee,S.K., Kim,M., Roh,J.K. (2011) Altered microRNA regulation in Huntington's 
disease models. Exp. Neurol., 227, 172-179. 
 276.  Luthi-Carter,R., Strand,A., Peters,N.L., Solano,S.M., Hollingsworth,Z.R., 
Menon,A.S., Frey,A.S., Spektor,B.S., Penney,E.B., Schilling,G., et al. (2000) 
Decreased expression of striatal signaling genes in a mouse model of 
Huntington's disease. Hum. Mol. Genet., 9, 1259-1271. 
 277.  Luthi-Carter,R., Hanson,S.A., Strand,A.D., Bergstrom,D.A., Chun,W., Peters,N.L., 
Woods,A.M., Chan,E.Y., Kooperberg,C., Krainc,D., et al. (2002) Dysregulation of 
gene expression in the R6/2 model of polyglutamine disease: parallel changes 
in muscle and brain. Hum. Mol. Genet., 11, 1911-1926. 
 278.  Marti,E., Pantano,L., Banez-Coronel,M., Llorens,F., Minones-Moyano,E., 
Porta,S., Sumoy,L., Ferrer,I., Estivill,X. (2010) A myriad of miRNA variants in 
control and Huntington's disease brain regions detected by massively parallel 
sequencing. Nucleic Acids Res., 38, 7219-7235. 
 279.  Schaffar,G., Breuer,P., Boteva,R., Behrends,C., Tzvetkov,N., Strippel,N., 
Sakahira,H., Siegers,K., Hayer-Hartl,M., Hartl,F.U. (2004) Cellular toxicity of 
polyglutamine expansion proteins: mechanism of transcription factor 
deactivation. Mol. Cell, 15, 95-105. 
 280.  Li,S.H., Cheng,A.L., Zhou,H., Lam,S., Rao,M., Li,H., Li,X.J. (2002) Interaction of 
Huntington disease protein with transcriptional activator Sp1. Mol. Cell Biol., 
22, 1277-1287. 
Page 46 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
47 
 
 281.  Steffan,J.S., Kazantsev,A., Spasic-Boskovic,O., Greenwald,M., Zhu,Y.Z., 
Gohler,H., Wanker,E.E., Bates,G.P., Housman,D.E., Thompson,L.M. (2000) The 
Huntington's disease protein interacts with p53 and CREB-binding protein and 
represses transcription. Proc. Natl. Acad. Sci. U. S. A, 97, 6763-6768. 
 282.  Zuccato,C., Tartari,M., Crotti,A., Goffredo,D., Valenza,M., Conti,L., 
Cataudella,T., Leavitt,B.R., Hayden,M.R., Timmusk,T., et al. (2003) Huntingtin 
interacts with REST/NRSF to modulate the transcription of NRSE-controlled 
neuronal genes. Nat. Genet., 35, 76-83. 
 283.  Seredenina,T., Luthi-Carter,R. (2012) What have we learned from gene 
expression profiles in Huntington's disease? Neurobiol. Dis., 45, 83-98. 
 284.  Lee,B., Butcher,G.Q., Hoyt,K.R., Impey,S., Obrietan,K. (2005) Activity-dependent 
neuroprotection and cAMP response element-binding protein (CREB): kinase 
coupling, stimulus intensity, and temporal regulation of CREB phosphorylation 
at serine 133. J. Neurosci., 25, 1137-1148. 
 285.  Lee,J., Kim,C.H., Simon,D.K., Aminova,L.R., Andreyev,A.Y., Kushnareva,Y.E., 
Murphy,A.N., Lonze,B.E., Kim,K.S., Ginty,D.D., et al. (2005) Mitochondrial cyclic 
AMP response element-binding protein (CREB) mediates mitochondrial gene 
expression and neuronal survival. J. Biol. Chem., 280, 40398-40401. 
 286.  Lonze,B.E., Ginty,D.D. (2002) Function and regulation of CREB family 
transcription factors in the nervous system. Neuron, 35, 605-623. 
 287.  Lonze,B.E., Riccio,A., Cohen,S., Ginty,D.D. (2002) Apoptosis, axonal growth 
defects, and degeneration of peripheral neurons in mice lacking CREB. Neuron, 
34, 371-385. 
 288.  Rosenfeld,M.G., Glass,C.K. (2001) Coregulator codes of transcriptional 
regulation by nuclear receptors. J. Biol. Chem., 276, 36865-36868. 
 289.  Chrivia,J.C., Kwok,R.P., Lamb,N., Hagiwara,M., Montminy,M.R., Goodman,R.H. 
(1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. 
Nature, 365, 855-859. 
 290.  Kwok,R.P., Lundblad,J.R., Chrivia,J.C., Richards,J.P., Bachinger,H.P., 
Brennan,R.G., Roberts,S.G., Green,M.R., Goodman,R.H. (1994) Nuclear protein 
CBP is a coactivator for the transcription factor CREB. Nature, 370, 223-226. 
 291.  Parker,D., Ferreri,K., Nakajima,T., LaMorte,V.J., Evans,R., Koerber,S.C., 
Hoeger,C., Montminy,M.R. (1996) Phosphorylation of CREB at Ser-133 induces 
complex formation with CREB-binding protein via a direct mechanism. Mol. Cell 
Biol., 16, 694-703. 
 292.  Radhakrishnan,I., Perez-Alvarado,G.C., Parker,D., Dyson,H.J., Montminy,M.R., 
Wright,P.E. (1997) Solution structure of the KIX domain of CBP bound to the 
Page 47 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
48 
 
transactivation domain of CREB: a model for activator:coactivator interactions. 
Cell, 91, 741-752. 
 293.  Ferreri,K., Gill,G., Montminy,M. (1994) The cAMP-regulated transcription factor 
CREB interacts with a component of the TFIID complex. Proc. Natl. Acad. Sci. U. 
S. A, 91, 1210-1213. 
 294.  Bourtchuladze,R., Frenguelli,B., Blendy,J., Cioffi,D., Schutz,G., Silva,A.J. (1994) 
Deficient long-term memory in mice with a targeted mutation of the cAMP-
responsive element-binding protein. Cell, 79, 59-68. 
 295.  Ravnskjaer,K., Kester,H., Liu,Y., Zhang,X., Lee,D., Yates,J.R., III, Montminy,M. 
(2007) Cooperative interactions between CBP and TORC2 confer selectivity to 
CREB target gene expression. EMBO J., 26, 2880-2889. 
 296.  Chan,H.M., La Thangue,N.B. (2001) p300/CBP proteins: HATs for transcriptional 
bridges and scaffolds. J. Cell Sci., 114, 2363-2373. 
 297.  Kalkhoven,E. (2004) CBP and p300: HATs for different occasions. Biochem. 
Pharmacol., 68, 1145-1155. 
 298.  Ogryzko,V.V., Schiltz,R.L., Russanova,V., Howard,B.H., Nakatani,Y. (1996) The 
transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell, 
87, 953-959. 
 299.  Vo,N., Goodman,R.H. (2001) CREB-binding protein and p300 in transcriptional 
regulation. J. Biol. Chem., 276, 13505-13508. 
 300.  Nucifora,F.C., Jr., Sasaki,M., Peters,M.F., Huang,H., Cooper,J.K., Yamada,M., 
Takahashi,H., Tsuji,S., Troncoso,J., Dawson,V.L., et al. (2001) Interference by 
huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular 
toxicity. Science, 291, 2423-2428. 
 301.  Sugars,K.L., Brown,R., Cook,L.J., Swartz,J., Rubinsztein,D.C. (2004) Decreased 
cAMP response element-mediated transcription: an early event in exon 1 and 
full-length cell models of Huntington's disease that contributes to 
polyglutamine pathogenesis. J. Biol. Chem., 279, 4988-4999. 
 302.  Steffan,J.S., Bodai,L., Pallos,J., Poelman,M., McCampbell,A., Apostol,B.L., 
Kazantsev,A., Schmidt,E., Zhu,Y.Z., Greenwald,M., et al. (2001) Histone 
deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in 
Drosophila. Nature, 413, 739-743. 
 303.  Sadri-Vakili,G., Bouzou,B., Benn,C.L., Kim,M.O., Chawla,P., Overland,R.P., 
Glajch,K.E., Xia,E., Qiu,Z., Hersch,S.M., et al. (2007) Histones associated with 
downregulated genes are hypo-acetylated in Huntington's disease models. 
Hum. Mol. Genet., 16, 1293-1306. 
Page 48 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
49 
 
 304.  Barco,A., Pittenger,C., Kandel,E.R. (2003) CREB, memory enhancement and the 
treatment of memory disorders: promises, pitfalls and prospects. Expert. Opin. 
Ther. Targets., 7, 101-114. 
 305.  Benito,E., Barco,A. (2010) CREB's control of intrinsic and synaptic plasticity: 
implications for CREB-dependent memory models. Trends Neurosci., 33, 230-
240. 
 306.  Silva,A.J., Kogan,J.H., Frankland,P.W., Kida,S. (1998) CREB and memory. Annu. 
Rev. Neurosci., 21, 127-148. 
 307.  Alarcon,J.M., Malleret,G., Touzani,K., Vronskaya,S., Ishii,S., Kandel,E.R., Barco,A. 
(2004) Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a 
model for the cognitive deficit in Rubinstein-Taybi syndrome and its 
amelioration. Neuron, 42, 947-959. 
 308.  Chen,G., Zou,X., Watanabe,H., van Deursen,J.M., Shen,J. (2010) CREB binding 
protein is required for both short-term and long-term memory formation. J. 
Neurosci., 30, 13066-13077. 
 309.  Valor,L.M., Pulopulos,M.M., Jimenez-Minchan,M., Olivares,R., Lutz,B., Barco,A. 
(2011) Ablation of CBP in forebrain principal neurons causes modest memory 
and transcriptional defects and a dramatic reduction of histone acetylation but 
does not affect cell viability. J. Neurosci., 31, 1652-1663. 
 310.  Oike,Y., Hata,A., Mamiya,T., Kaname,T., Noda,Y., Suzuki,M., Yasue,H., 
Nabeshima,T., Araki,K., Yamamura,K. (1999) Truncated CBP protein leads to 
classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a 
dominant-negative mechanism. Hum. Mol. Genet., 8, 387-396. 
 311.  Saura,C.A., Choi,S.Y., Beglopoulos,V., Malkani,S., Zhang,D., Shankaranarayana 
Rao,B.S., Chattarji,S., Kelleher,R.J., III, Kandel,E.R., Duff,K., et al. (2004) Loss of 
presenilin function causes impairments of memory and synaptic plasticity 
followed by age-dependent neurodegeneration. Neuron, 42, 23-36. 
 312.  Wood,M.A., Kaplan,M.P., Park,A., Blanchard,E.J., Oliveira,A.M., Lombardi,T.L., 
Abel,T. (2005) Transgenic mice expressing a truncated form of CREB-binding 
protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory 
storage. Learn. Mem., 12, 111-119. 
 313.  Korzus,E., Rosenfeld,M.G., Mayford,M. (2004) CBP histone acetyltransferase 
activity is a critical component of memory consolidation. Neuron, 42, 961-972. 
 314.  Rouaux,C., Loeffler,J.P., Boutillier,A.L. (2004) Targeting CREB-binding protein 
(CBP) loss of function as a therapeutic strategy in neurological disorders. 
Biochem. Pharmacol., 68, 1157-1164. 
 315.  Vecsey,C.G., Hawk,J.D., Lattal,K.M., Stein,J.M., Fabian,S.A., Attner,M.A., 
Cabrera,S.M., McDonough,C.B., Brindle,P.K., Abel,T., Wood,M.A. (2007) Histone 
Page 49 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
50 
 
deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-
dependent transcriptional activation. J. Neurosci., 27, 6128-6140. 
 316.  Killoran,A., Biglan,K.M. (2014) Current therapeutic options for Huntington's 
disease: good clinical practice versus evidence-based approaches? Mov Disord., 
29, 1404-1413. 
 317.  Bender,A.T., Beavo,J.A. (2006) Cyclic nucleotide phosphodiesterases: molecular 
regulation to clinical use. Pharmacol. Rev., 58, 488-520. 
 318.  Blokland,A., Schreiber,R., Prickaerts,J. (2006) Improving memory: a role for 
phosphodiesterases. Curr. Pharm. Des, 12, 2511-2523. 
 319.  Puzzo,D., Sapienza,S., Arancio,O., Palmeri,A. (2008) Role of phosphodiesterase 
5 in synaptic plasticity and memory. Neuropsychiatr. Dis. Treat., 4, 371-387. 
 320.  Siuciak,J.A. (2008) The role of phosphodiesterases in schizophrenia : 
therapeutic implications. CNS. Drugs, 22, 983-993. 
 321.  Xu,Y., Zhang,H.T., O'Donnell,J.M. (2011) Phosphodiesterases in the central 
nervous system: implications in mood and cognitive disorders. Handb. Exp. 
Pharmacol.,  204, 447-485. 
 322.  Giralt,A., Saavedra,A., Carreton,O., Arumi,H., Tyebji,S., Alberch,J., Perez-
Navarro,E. (2013) PDE10 inhibition increases GluA1 and CREB phosphorylation 
and improves spatial and recognition memories in a Huntington's disease 
mouse model. Hippocampus, 23, 684-695. 
 323.  Niccolini,F., Haider,S., Reis,M.T., Muhlert,N., Tziortzi,A.C., Searle,G.E., 
Natesan,S., Piccini,P., Kapur,S., Rabiner,E.A., et al. (2015) Altered PDE10A 
expression detectable early before symptomatic onset in Huntington's disease. 
Brain, 138, 3016-3029. 
 324.  Russell,D.S., Jennings,D.L., Barret,O., Tamagnan,G.D., Carroll,V.M., Caille,F., 
Alagille,D., Morley,T.J., Papin,C., Seibyl,J.P., Marek,K.L. (2016) Change in PDE10 
across early Huntington disease assessed by [18F]MNI-659 and PET imaging. 
Neurology, 86, 748-754. 
 325.  Giampa,C., Patassini,S., Borreca,A., Laurenti,D., Marullo,F., Bernardi,G., 
Menniti,F.S., Fusco,F.R. (2009) Phosphodiesterase 10 inhibition reduces striatal 
excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol. 
Dis., 34, 450-456. 
 326.  Giampa,C., Laurenti,D., Anzilotti,S., Bernardi,G., Menniti,F.S., Fusco,F.R. (2010) 
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal 
and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS. 
One., 5, e13417. 
Page 50 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
51 
 
 327.  Hebb,A.L., Robertson,H.A. (2007) Role of phosphodiesterases in neurological 
and psychiatric disease. Curr. Opin. Pharmacol., 7, 86-92. 
 328.  Kleiman,R.J., Kimmel,L.H., Bove,S.E., Lanz,T.A., Harms,J.F., Romegialli,A., 
Miller,K.S., Willis,A., des,E.S., Kuhn,M., Schmidt,C.J. (2011) Chronic suppression 
of phosphodiesterase 10A alters striatal expression of genes responsible for 
neurotransmitter synthesis, neurotransmission, and signaling pathways 
implicated in Huntington's disease. J. Pharmacol. Exp. Ther., 336, 64-76. 
 329.  Heckman,P.R., van Duinen,M.A., Bollen,E.P., Nishi,A., Wennogle,L.P., 
Blokland,A., Prickaerts,J. (2016) Phosphodiesterase inhibition and regulation of 
dopaminergic frontal and striatal functioning: clinical implications. Int. J. 
Neuropsychopharmacol. Apr 30. doi: 10.1093/ijnp/pyw030. (Epub ahead of 
print). 
 330.  Alberch,J., Perez-Navarro,E., Canals,J.M. (2004) Neurotrophic factors in 
Huntington's disease. Prog. Brain Res., 146, 195-229. 
 331.  Arregui,L., Benitez,J.A., Razgado,L.F., Vergara,P., Segovia,J. (2011) Adenoviral 
astrocyte-specific expression of BDNF in the striata of mice transgenic for 
Huntington's disease delays the onset of the motor phenotype. Cell Mol. 
Neurobiol., 31, 1229-1243. 
 332.  Gharami,K., Xie,Y., An,J.J., Tonegawa,S., Xu,B. (2008) Brain-derived 
neurotrophic factor over-expression in the forebrain ameliorates Huntington's 
disease phenotypes in mice. J. Neurochem., 105, 369-379. 
 333.  Simmons,D.A., Mehta,R.A., Lauterborn,J.C., Gall,C.M., Lynch,G. (2011) Brief 
ampakine treatments slow the progression of Huntington's disease phenotypes 
in R6/2 mice. Neurobiol. Dis., 41, 436-444. 
 334.  Bibb,J.A., Yan,Z., Svenningsson,P., Snyder,G.L., Pieribone,V.A., Horiuchi,A., 
Nairn,A.C., Messer,A., Greengard,P. (2000) Severe deficiencies in dopamine 
signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. U. 
S. A, 97, 6809-6814. 
 335.  Chiba,K., Adachi,K. (2012) Discovery of fingolimod, the sphingosine 1-
phosphate receptor modulator and its application for the therapy of multiple 
sclerosis. Future. Med. Chem., 4, 771-781. 
 336.  Di,P.A., Amico,E., Favellato,M., Castrataro,R., Fucile,S., Squitieri,F., Maglione,V. 
(2014) FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in 
cellular and mouse models of Huntington disease. Hum. Mol. Genet., 23, 2251-
2265. 
 337.  Lee,C.F., Chern,Y. (2014) Adenosine receptors and Huntington's disease. Int. 
Rev. Neurobiol., 119, 195-232. 
Page 51 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
52 
 
 338.  Popoli,P., Blum,D., Martire,A., Ledent,C., Ceruti,S., Abbracchio,M.P. (2007) 
Functions, dysfunctions and possible therapeutic relevance of adenosine A2A 
receptors in Huntington's disease. Prog. Neurobiol., 81, 331-348. 
 339.  Popoli,P. (2008) Regulation of brain functions by A2A receptors: implication for 
therapeutics. Curr. Pharm. Des, 14, 1466-1467. 
 340.  Puerta,E., Hervias,I., Barros-Minones,L., Jordan,J., Ricobaraza,A., Cuadrado-
Tejedor,M., Garcia-Osta,A., Aguirre,N. (2010) Sildenafil protects against 3-
nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and 
BDNF. Neurobiol. Dis., 38, 237-245. 
 341.  Mitsuishi,M., Miyashita,K., Itoh,H. (2008) cGMP rescues mitochondrial 
dysfunction induced by glucose and insulin in myocytes. Biochem. Biophys. Res. 
Commun., 367, 840-845. 
 342.  Chaturvedi,R.K., Beal,M.F. (2013) Mitochondria targeted therapeutic 
approaches in Parkinson's and Huntington's diseases. Mol. Cell Neurosci., 55, 
101-114. 
 343.  Peixoto,C.A., Nunes,A.K., Garcia-Osta,A. (2015) Phosphodiesterase-5 Inhibitors: 
Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, 
and Cognition. Mediators. Inflamm., 2015, 940207. 
 344.  Threlfell,S., West,A.R. (2013) Modulation of striatal neuron activity by cyclic 
nucleotide signaling and phosphodiesterase inhibition. Basal. Ganglia., 3, 137-
146. 
 345.  Threlfell,S., Sammut,S., Menniti,F.S., Schmidt,C.J., West,A.R. (2009) Inhibition of 
phosphodiesterase 10A increases the responsiveness of striatal projection 
neurons to cortical stimulation. J. Pharmacol. Exp. Ther., 328, 785-795. 
 346.  Padovan-Neto,F.E., Sammut,S., Chakroborty,S., Dec,A.M., Threlfell,S., 
Campbell,P.W., Mudrakola,V., Harms,J.F., Schmidt,C.J., West,A.R. (2015) 
Facilitation of corticostriatal transmission following pharmacological inhibition 
of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-
cGMP signaling pathways. J. Neurosci., 35, 5781-5791. 
 347.  Jiang,H., Poirier,M.A., Liang,Y., Pei,Z., Weiskittel,C.E., Smith,W.W., 
DeFranco,D.B., Ross,C.A. (2006) Depletion of CBP is directly linked with cellular 
toxicity caused by mutant huntingtin. Neurobiol. Dis., 23, 543-551. 
 348.  McCampbell,A., Taye,A.A., Whitty,L., Penney,E., Steffan,J.S., Fischbeck,K.H. 
(2001) Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl. 
Acad. Sci. U. S. A, 98, 15179-15184. 
 349.  Taylor,J.P., Taye,A.A., Campbell,C., Kazemi-Esfarjani,P., Fischbeck,K.H., Min,K.T. 
(2003) Aberrant histone acetylation, altered transcription, and retinal 
Page 52 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
53 
 
degeneration in a Drosophila model of polyglutamine disease are rescued by 
CREB-binding protein. Genes Dev., 17, 1463-1468. 
 350.  Ferrante,R.J., Kubilus,J.K., Lee,J., Ryu,H., Beesen,A., Zucker,B., Smith,K., 
Kowall,N.W., Ratan,R.R., Luthi-Carter,R., Hersch,S.M. (2003) Histone 
deacetylase inhibition by sodium butyrate chemotherapy ameliorates the 
neurodegenerative phenotype in Huntington's disease mice. J. Neurosci., 23, 
9418-9427. 
 351.  Gardian,G., Browne,S.E., Choi,D.K., Klivenyi,P., Gregorio,J., Kubilus,J.K., Ryu,H., 
Langley,B., Ratan,R.R., Ferrante,R.J., Beal,M.F. (2005) Neuroprotective effects 
of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's 
disease. J. Biol. Chem., 280, 556-563. 
 352.  Jia,H., Morris,C.D., Williams,R.M., Loring,J.F., Thomas,E.A. (2015) HDAC 
inhibition imparts beneficial transgenerational effects in Huntington's disease 
mice via altered DNA and histone methylation. Proc. Natl. Acad. Sci. U. S. A, 
112, E56-E64. 
 353.  Jia,H., Wang,Y., Morris,C.D., Jacques,V., Gottesfeld,J.M., Rusche,J.R., 
Thomas,E.A. (2016) The effects of pharmacological inhibition of histone 
deacetylase 3 (HDAC3) in Huntington's disease mice. PLoS. One., 11, e0152498. 
 354.  Kumar,A., Kumar,S.S., Kumar,V., Kumar,D., Agarwal,S., Rana,M.K. (2015) 
Huntington's disease: an update of therapeutic strategies. Gene, 556, 91-97. 
 
 
 
 
Page 53 of 59
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology
This article is protected by copyright. All rights reserved.
Table 1. Genetically modified HD mouse models.  
 
Mouse model Construct Promoter CAG 
repeat size 
Lifespan References 
R6/1 Insertion of the exon 
1 of human HD gene 
into mouse genome 
Human 
huntingtin 
116 
 
32-40 w 
 
(12, 77-79) 
R6/2 
 
Insertion of the exon 
1 of human HD gene 
into mouse genome 
Human 
huntingtin 
144 13-16 w (12, 77-80) 
N171-82Q 
 
Insertion of the first 
171 aa from the N-
terminal fragment of 
the human HD gene 
into mouse genome 
Mouse 
prion 
protein 
 
82 
 
16-24 w 
 
(81) 
HD94- tet off 
 
Insertion of a 
chimeric 
mouse/human exon 
1 fragment with 
polyQ expansion into 
mouse genome 
CamKIIa- 
tTA 
 
94 
 
Normal 
 
(82) 
YAC72 
 
Yeast artificial 
chromosome 
expressing full-length 
human mutant 
huntingtin 
Human 
huntingtin 
 
72 
 
Normal 
 
(83-85) 
YAC128 
 
Yeast artificial 
chromosome 
expressing full-length 
human mutant 
huntingtin 
Human 
huntingtin 
 
128 
 
Normal 
 
(86-90) 
BACHD 
 
Bacterial artificial 
chromosome 
expressing  full-
length human 
mutant huntingtin 
Human 
huntingtin 
 
97 
CAG/CAA 
mixed 
repeats 
Normal 
 
(76, 87, 91, 92) 
Hdh92Q 
 
Replacing exon 1 of 
the mouse huntingtin 
gene with a mutant 
human exon 1 
Mouse 
huntingtin 
 
92 
 
Normal 
 
(93-95) 
Hdh111Q Replacing exon 1 of 
the mouse huntingtin 
gene with a mutant 
Mouse 
huntingtin 
111 Normal (94-97) 
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 human exon 1    
CAG140 
 
Inserting CAG 
repeats into the 
mouse huntingtin 
gene 
Mouse 
huntingtin 
 
140 
 
Normal 
 
(98) 
CAG150 
 
Inserting CAG 
repeats into the 
mouse huntingtin 
gene 
Mouse 
huntingtin 
 
150 
 
Normal 
 
(99-101) 
 
Information about construct insertion, the promoter used to express the mutation, the CAG 
repeat number and the lifespan. Weeks (w). 
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Table 2. Alterations in synaptic plasticity in HD mouse models.  
 
Mouse 
model 
Cerebral cortex Striatum Hippocampus References 
R6/1 
 
Loss of cortical plasticity 
(8-10 w) 
Increased LTD (2 mo) 
followed by a reduction in 
LTD expression (5 mo) 
and loss of LTD (7-9 mo) 
at perirhinal synapses 
Decreased dendritic spine 
density and spine length 
(8 mo) 
Decreased 
spontaneous EPSCs 
in MSNs (9-13 mo) 
Increased 
spontaneous IPSCs 
(12-15 mo) 
Decreased dendritic 
spine density and 
spine length (8 mo) 
Decreased LTP in 
brain slices (5 w) 
Impaired LTP in vivo 
(13-14 w) 
Increased LTD at CA1 
synapses (12 w) 
Decreased dendritic 
spine density (20 w) 
(102-112) 
R6/2 Hyperexcitable cortex  
and greater susceptibility 
to seizures (3 w) 
Increased spontaneous 
IPSCs (3-4 w) 
Decreased spontaneous 
IPSCs and increased 
spontaneous EPSCs (13 w) 
Dendritic spine loss  
(3-4 w) 
 
Progressive 
decrease in 
spontaneous EPSCs 
in MSNs (5-7 w) 
No differences in 
the LF IPSCs 
Increased 
spontaneous IPSCs 
(5-7 w and 9-14 w) 
Progressive 
dendritic spine loss 
(4-10 w) 
Reduced LTP and 
aberrant LTD at CA1 
synapses (5 w) 
 
(67, 104, 113-
123) 
 Dysfunctional communication between 
cortex and striatum  
(7-9 w) 
   
YAC72 Increased NMDAR-mediated EPSCs in MSNs 
(21-31 d) after stimulation of cortical 
afferents in corticostriatal slices 
Altered early corticostriatal synaptic function 
(21-30 d), including presynaptic dysfunction 
and propensity towards synaptic depression 
 Increased LTP (6 mo) 
Reduced LTP (10 mo) 
 
(83, 124-126) 
YAC128 
 
Altered early corticostriatal synaptic function 
(21-30 d) 
Presynaptic dysfunction, propensity towards 
synaptic depression and altered AMPAR function 
Biphasic age-dependent changes in 
Reduced paired-pulse 
depression in the DG 
(3-6 mo) 
Enhanced post-
tetanic and short-
term potentiation 
(104, 115, 
127-131) 
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corticostriatal function:  
Increased synaptic currents and glutamate 
release (1 mo) 
Reduced evoked synaptic currents and glutamate 
release (7-12 mo) 
after HF stimulation 
(3-6 mo) 
 
 Increased spontaneous 
EPSCs (12 mo) 
Increase spontaneous 
IPSCs (6 and 12 mo) 
Reduced 
spontaneous EPSCs 
(6  and 12 mo) 
Reduced 
spontaneous LF 
IPSCs (6 and 12 mo)  
Increased 
spontaneous HF 
IPSCs (1, 2, 12 mo) 
Progressive 
dendritic spine 
density loss  
(3, 6, 12 mo) 
  
BACHD 
 
Progressive reduction of 
cortical excitation and 
inhibition of layer 2/3 
pyramidal cells (3-6 mo) 
 
Progressive 
reduction of 
excitation onto 
MSNs (3-6 mo) 
High excitability of 
MSNs (18 mo) 
Reduced dendritic 
spine density  
(18 mo) 
n.r. 
 
(87, 91, 92, 
132, 133) 
Hdh92Q n.r. n.r. Reduced LTP  
(4-6 mo) 
(134) 
Hdh111Q n.r. 
 
n.r. 
 
Reduced LTP (2 mo) 
Reduced actin 
polymerization in 
dendritic spines after 
TBS-induced LTP 
(134) 
Hdh 
7Q/111Q 
 
Impaired induction and maintenance of 
corticostriatal LTP (2 and 4 mo) 
 
 
Reduced LTP (6 mo) 
Decreased dendritic 
spine density and 
altered distribution 
with a specific 
reduction in the 
(135, 136) 
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proportion of thin 
spines (8 mo) 
 Decreased dendritic spine 
density and a shift in their 
distribution (2 mo) 
Progressive decrease of 
glutamatergic excitatory 
postsynaptic sites  
(2 and 8 mo) 
No alterations in 
dendritic spine 
density (2 mo) 
Decrease of 
glutamatergic 
excitatory 
postsynaptic sites  
(8 mo) 
  
CAG140 
 
Increased spontaneous 
EPSCs (12 mo) 
Increased spontaneous 
IPSCs (6 and 12 mo) 
 
Reduced 
spontaneous EPSCs 
(12 and 18 mo) 
Reduced 
spontaneous LF 
IPSCs  
(12 and 18 mo) 
 
Increased 
spontaneous HF 
IPSCs (12 mo) 
Reduced 
thalamostriatal 
axondendritic 
terminals (1 mo) 
Loss of 
corticostriatal 
terminals (12 mo) 
Reduced dendritic 
spines in MSNs  
(20-26 mo) 
n.r. 
 
(104, 115, 
137, 138) 
 
Alterations in synaptic plasticity (electrophysiological properties and dendritic spine 
density/morphology) of neuronal populations from the cerebral cortex, striatum and 
hippocampus of HD mouse models. Long-term depression (LTD); Long-term potentiation (LTP); 
Excitatory postsynaptic currents (EPSCs); Inhibitory postsynaptic currents (IPSCs); Cornus 
Ammonis 1 (CA1); Medium-sized spiny neurons (MSNs); N-methyl-D-aspartate receptor 
(NMDAR); α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor (AMPAR); Dentate 
gyrus (DG); low frequency (LF); high frequency (HF); Theta burst stimulation (TBS); Weeks (w); 
Months (mo); Not reported (n.r.). 
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Table 3. Cognitive, psychiatric and motor deficits in HD mouse models.  
 
Mouse model Cognitive and psychiatric 
deficits 
Motor deficits References 
R6/1 8-12 w 14 w 
8 w (AR) 
(79, 102, 106, 136, 
139) 
R6/2 4-8 w 6-8 w (79, 120, 140-142) 
N171-82Q 14 w 11 w (81, 143, 144) 
HD94- tet off n.r. 4 w (82, 145) 
YAC72 n.r. Hyperactivity (7-9 mo) 
16  mo 
(83) 
YAC128 
 
7-8.5 mo 
 
Hyperkinesia (3 mo) 
Hypokinesia (6 mo) 
2-12 mo (AR) 
(87, 88, 90, 146, 
147) 
BACHD 2-12 mo 2-12 mo (AR) (76, 87, 91, 92) 
Hdh92Q 4 mo 21 mo (148, 149) 
Hdh111Q n.r. 24 mo (96) 
Hdh7Q/111Q 6 mo 8 mo 
2-6 mo (AR) 
(135, 136, 150-152) 
CAG140 
 
4-6 mo 
 
Hyperkinesia (1-3 mo) 
Hypokinesia (from 3 mo) 
4-12 mo  
(98, 153) 
CAG150 4 mo 4-10 mo (100, 154) 
 
Information about the age at which HD models start to exhibit cognitive, psychiatric and motor 
deficits. Motor deficits include several parameters: 1) learning of new motor skills (evaluated 
with the accelerating rotarod (AR) task), 2) hypo/hyperactivity, and 3) motor coordination 
(evaluated using several motor tests). Specific information about each model can be found in 
the cited references. Weeks (w); Months (mo); Not reported (n.r.). 
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